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Abstract
Urinary tract infections are diagnosed in female populations primarily in ambulatory care
settings in the United States. Yet, published evidence documents that many of the
antibiotics prescribed in these settings are unnecessary, erroneous, or, inappropriately
prescribed. Improper management of uncomplicated urinary tract infections in
nonpregnant women has resulted in higher morbidity rates due to antibiotic resistance.
The purpose of this retrospective observational cohort study was to explore a current
national database for associations between nonpregnant American female patients who
were exposed to poverty and at risk for urinary tract infection antibiotic resistance in an
ambulatory care setting. Krieger’s ecosocial theory was utilized as the study’s theoretical
foundation to complement current public health social change priorities. Data from the
National Ambulatory Medical Care Survey were analyzed to explore potential
associations with urinary tract infections and antibiotic resistance. The sample consisted
of ambulatory patients with urinary tract infection symptoms (n=45). The independent
variables selected were antibiotics prescribed initially in 3 months or less after the onset
of urinary tract infection symptoms, the continuation of antibiotics prescribed in 12
months or less after recurrence, and three classes of antibiotics prescribed for urinary
tract infection symptoms known as broad-spectrum, narrow-spectrum, and combined
broad- and narrow-spectrum antibiotics, while the dependent variable was urinary tract
infection antibiotic resistance. Relationships between the variables were analyzed using
binary logistic regression, however, there were no statistically significant outcomes.
Promoting antibiotic stewardship programs in all health care settings in the U.S. can
effect positive social changes that will prevent further antibiotic resistance.
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Chapter 1: Introduction to the Study
In the first half of the 20th century, the invention and application of antibiotics
astonished us to treat infections (Davies & Davies, 2010; Landecker, 2015).
Astonishment has shifted to concern about uncomplicated urinary tract infections (UTIs),
which medical experts have classified as the primary cause of morbidity in females in the
United States. (Ciani, Grassi, & Terricone, 2013; Soto, 2014). Disparities in low-income
female populations demonstrate substandard quality in health care recommendations and
treatment for uncomplicated UTI infections (Kaiser Family Foundation, 2016).
Antibiotic-resistance complications in UTIs are now considered a global public health
crisis (Lee, Cho, Jeong, & Lee, 2013).
The incidence and prevalence of antibiotic-resistant UTIs in ambulatory care
settings, which include those settings that are specific to outpatient versus inpatient care,
have been well-studied across all populations in developing and developed countries
outside of the United States (August & DeRosa, 2012). Research in ambulatory care
settings for uncomplicated UTIs in the United States have focused on comparing
prescribing patterns in pediatric, older adult, and pregnant populations (May, Mullins, &
Pines, 2014; Matuszkiewicz-Rowynska, Malyszko, & Wieliczko, 2015). Researchers
have not examined the impact of social determinants such as economic status in the
prescribing of antibiotics for UTIs in these settings, according to Kobayashi, Shapiro,
Hersh, Sanchez, and Hicks (2016).
In 2015, the U.S. Department of Health and Human Services (HHS; 2015) reestablished goals after noting that between 2001-2014, health care disparities had made
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little progress. Federal initiatives for health care research, policy makers have requested
that vulnerable community populations such as low-income women be prioritized in
studies (Agency for Healthcare Research and Quality [AHRQ], 2016). An opportunity
currently exists to examine the impact of antibiotic resistance and the methods used to
prescribe antibiotics for uncomplicated UTIs in nonpregnant, low-income women in U.S.
ambulatory care settings. This study may promote positive social change by helping
health care practitioners and organizations to reduce barriers in low-income, nonpregnant
women’s access to quality care in the management of UTIs in ambulatory care settings.
In Chapter 1, I provide descriptive, clinically-related details about antibiotic
resistance and UTIs. In support of this study’s direction, I also illustrate the complexities
of antibiotic resistance patterns related to biomedical implications, epidemiology,
economic burden, and the global impact of antibiotic resistance in ambulatory care
settings. Additionally, UTI pathogenicity, clinical significance, epidemiology, economic
burden, and the relevant impacts of antibiotic prescribing for these infections are
examined.
Background
Urinary Tract Microbiology and Pathogenesis
The urinary tract system in and out of the human body consists of normal flora.
Normal flora are also known as common commensals; they present on (exogenous) or in
(endogenous) humans as gram positive or negative, or fungal organisms (Findley &
Grice, 2014). Common commensals may become altered in a human host environment
due to antibiotic influence, coexisting disease, income, genetics, diet, stress, age, or,
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environmental factors (Grice & Segre, 2011; Marrie, Swantee, & Hartlen, 1980). Human
UTIs are the most common type of infection caused by bacteria (Nienhouse et al., 2014).
UTIs may be caused by voiding urine, when the entryway to the genitourinary tract opens
(August & De Rosa, 2012). Researchers once thought the inside of the urinary tract to be
a sterile environment, yet they recently found that bacteria live in the human host (2012;
Flores-Mireles, Walker, Caparon, & Hultgren, 2015; Hilt et al., 2014; SantiagoRodriguez, Ly, Bonilla, & Pride, 2015). Bacteria normally living in the urinary tract may
cause infections but do not normally lead to death (Nicolle, 2014).
Urinary Tract Infection Clinical Significance
Urinary tract infections are clinically significant because urinary tract lab findings
produce positive results which usually lead to a diagnosis of UTI and subsequent
antibiotic treatment (Grabe et al., 2014). Researchers conducting global studies have
found that 50-60% of females under the age of 50 with a low-income status appear to be
at considerable risk for UTIs (Al-Badir, & Al-Shaikh, 2013; Minardi, d’Anzeo, Cantoro,
Conti, & Muzzonigro, 2011). Anatomical issues (specifically, the urethral location in
females) and behavior issues (e.g., noncompliance with medications) appear to correlate
with poor clinical outcomes related to antimicrobial resistance (Barber, Norton, Spivak,
& Mulvey, 2013; Minardi, d’Anzeo, Cantoro, Conti, & Muzzonigro, 2011; Mohsin &
Siddiqui, 2010;). Recurrent UTIs are described as involved in 19% of younger, sexually
active female populations that have a diagnosis of cystitis, which is a type of lower UTI
(Soto et al., 2006). When initial treatment fails, recurrent UTIs may develop
antimicrobial resistance (Ejrnaes, 2010; Bodro, 2015). Clinically-significant management
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of UTIs, according to Mohsin and Siddique (2010), involves use of evidence-based
guidelines for the clinical management of infections and is dependent on resources,
clinical experience, and training.
Urinary Tract Infection Epidemiology
Bacterial UTIs are one of the most common infections treated in ambulatory care
settings (Lema, 2015). Brusch and Bronze (2015) stated that one in five women will be
diagnosed with a UTI in their lifetime. Data from AHRQ (2014), a U.S. federal health
care agency, revealed that the incidence of UTIs in ambulatory care settings was highest
in female patients as evidenced by 13 infections per 10,000 in the broader U.S.
population. In the hospital setting, it was noted that there were 4 infections per 10,000 in
the U.S. population, (AHRQ, 2014). Current research data indicate that females with
complaints of UTI symptoms account for 85% of the 3 million appointments made in
ambulatory care settings in the United States (Thoureen, Scott, & Best, 2015). In
nonpregnant females who evidence cystitis for the first time, recurrence occurs at least
30-44% of the time (Gupta & Trautner, 2013).
Females of all ages are at risk for UTIs (Lema, 2015). However, women who are
age 30-60 have a greater incidence of acute UTIs with the mean incidence peak between
15 to 39 years of age (AHRQ, 2014; Centers for Disease Control & Prevention [CDC],
2014, 2015). Adult women account for around 10% of all symptomatic UTIs annually,
and 1 in 3 of these will need antibiotic treatment (Lawal, 2012). Uncomplicated UTIs
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have been studied without consideration for social determinants in female populations
(Brusch & Bronze, 2015; Hawker et al., 2014). Researchers have documented that
hospitalized, pregnant female patients currently have the highest incidence rates of
complicated UTIs (AHRQ, 2014; Czaja, Scholes, Hooton, & Stamm, 2007).
Urinary Tract Infection Economic Burden
Over 9 million ambulatory care visits are made annually in the United States for
UTIs diagnosed as cystitis (Wagenlehner & Naber, n.d.). Annually, the estimated cost of
antibiotic agents prescribed for the treatment of symptomatic or asymptomatic UTIs are
over 1 billion dollars, which accounts for 15% of the total money spent by the public on
these drugs (Wagenlehner& Naber, n.d.). Poverty, access to care, or inappropriate disease
management may lead to prolonged or complex care that becomes a significant drain on
insurance policies carried by groups or individuals (Thorpe, Wisniewski, & Lindsay,
2009).
The overall economic burden to patients is high for any disease treatment that
involves multiple tests and medications. however the costs associated with antibioticresistant UTIs are much higher and account for at least a 35% to 47% increase in total
patient costs (Roley & Truscott, 2013). Nonpregnant low-income female populations in
the United States, in particular, face a considerable financial burden (Shartzer, Long, &
Benatar, 2015). Medicaid, a source of payment for health care coverage, represents low
income as a social determinant (Blumberg, 2012). Patients who receive care in
ambulatory care settings may manifest UTI antibiotic resistance patterns related to having
Medicaid as their insurance (Alsan et al., 2015). However, studies indicate that even with
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the Affordable Care Act in place, disparities continue to exist for low-income women
(Alsan, et al, 2015).
Antibiotic Resistance Economic Burden
According to Gandra, Barter, and Laxminarayan (2014), the economic impacts of
antibiotic resistance in the United States, and the frequency by which the costs directly
concern the public, health care administration, patients, doctors, and pharmaceutical
companies, appears to have been poorly documented until recently. Lack of attention to
these issues has continued to be a concern, Gandra, Bater, and Laxminarayan asserted. In
the United States, researchers have estimated the economic burden of health care cost for
infections that are antibiotic-resistant to be approximately $20 billion, with over $34
billion attributed to a loss in workforce productivity (Bartlett, Gilberg, & Spellberg,
2013; CDC, 2011a, 2011b, 2015b; Taylor et al., 2014; Song et al., 2015).
Antibiotic Resistance Biomedical Implications
Antibiotic drugs are a class of chemical substances that are formed as medicine to
treat bacterial infections by slowing down or destroying bacterial growth (Fair & Tor,
2014). McGowan (2008) noted that antibiotic resistance has a significant impact on
incidence outcomes in community UTIs, for example, resistance to current antibiotic
agents has increased due to the inappropriate use of these drugs (Nathan & Cars, 2014).
Antibiotic Resistance Epidemiology
Antibiotic resistance strain incidence and prevalence rates continue to climb
without the development of new antibiotics (Hawkey & Jones, 2009). Surveillance efforts
to generalize and understand the increase in incidence rates of antibiotic-resistant
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pathogens is confined to the acute care hospital environment (Sydnor & Perl, 2011).
Limited syndromic surveillance in the community is controlled primarily by the strength
of funding provided for agricultural and human population studies (Phalkey, Yamamoto,
Awate, & Marx, 2013). Ongoing efforts to establish campaigns to promote judicious use
of all antibiotics continue in the United States (Purcell, 2012). However, as awareness
grows, the pace for the creation of new antibiotics has slowed (Boucher et al., 2009;
Sundqvist, 2014). Failure to provide a solution for antibiotic-resistant infections has led
to the escalation of human, human-to-animal, and animal-to-human pathogenic
transmission (Hawkey & Jones, 2009).
Problem Statement
The current public health-antibiotic-resistance crisis is due to inappropriate
infection management as evidenced by many factors. Low-income populations are at a
higher risk for antibiotic resistance due to the inappropriate medical management of
infectious diseases (Shartzer et al., 2015). Inappropriate antibiotic prescribing has also
been reported with over 47 million (more than 30%) antibiotics prescribed annually in the
United States. (Shapiro, Hicks, Pavia, & Hersh, 2013; Ventola, 2015). Urinary tract
infection diagnosis in U.S. female populations comprises more than 84% of the 3 million
patients who report to ambulatory care facilities with UTI symptoms (Thoureen, Scott, &
Best, 2015). The CDC (2013a) reported that 50% of the antibiotics that are prescribed in
ambulatory care settings are unnecessary or suboptimal and, also, empirically prescribed
without laboratory confirmation of an infection. Health-care providers are challenged to
provide low-cost, generic substitutions when dictated by insurance plans; many
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antibiotics may not have a generic substitution (Garau, Nicolau, & Bassetti, 2014;
Pronovost, 2013).
The rate of uncomplicated UTIs in women between the ages of 18-49 in the
United States who are managed in the ambulatory care setting and receive antibiotic
treatment is 28.2% for every 10,000 females (Lawal, 2012). Pregnant, pediatric, or older
adult females with a lower economic status in developed countries such as the United
States are often reported in the literature as having a high risk for antibiotic-resistant
infections such as UTIs (Lawal, 2012). Research reports since the 1980’s provide
evidence that inappropriate patient infection management by providers is the primary
problem leading to antibiotic resistance in UTIs (Vasudevan, 2014).
A gap in the literature exists because U.S. researchers have not examined income
distribution in nonpregnant females with UTI complaints in ambulatory care settings
(Kobayashi, 2016; May et al., 2014). An opportunity existed to study nonpregnant
females, with Medicaid recipient status representing low-income status. This research gap
has contributed to antibiotic-resistant UTIs in a population already known to be high-risk
(Ciani et al., 2013). Social change can occur by studying the exposures and risks related
to ambulatory care antibiotic management for UTIs. This social change concept to study
UTI antibiotic management suggested further that there is logic to seeking an increase in
funding for future research. For example, research could
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include case-control studies aimed at improving care management of all health care
problems in low-income populations in ambulatory care settings.
Purpose of the Study
The purpose of this quantitative study was to examine nonpregnant American
female patients who were exposed to poverty, as evidenced by the reported payment type
of Medicaid, as the reported payment type, and at risk for antibiotic resistance when
seeking care for UTIs in ambulatory care settings. Low-income indicators such as
insurance type may negatively impact outcomes of antibiotic resistance reduction efforts
(Laxminarayan et al., 2013). The significance of this study contributed to the increase in
awareness of risks of antibiotic resistance related to poor outcomes in uncomplicated
infections such as UTIs. This study was designed to predict outcomes that are associated
with risks related to antibiotic resistance in low-income nonpregnant female populations
on Medicaid.
Research Questions and Hypotheses
Three research questions governed this study. The outcome (or, dependent)
variable of interest was UTI antibiotic resistance (UAR). The independent variables were
initial antibiotics, continued antibiotics, and broad-spectrum, narrow-spectrum, and a
combination of broad- and narrow-spectrum antibiotics prescribed. The research
questions were grounded by the ecosocial theory. This study’s research questions
incorporated proximal and distal associations with disease process and outcomes.
Krieger, the founder of ecosocial theory (2008), stated that proximal associations can
only be changed by a patient or his or her provider; however, society must work to
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change distal associations such as payment amounts for provider services (p. 223). Social
patterns constantly change due to pathways, power, and levels that are proximally and
distally associated (2008).
Research Question 1: Are initial antibiotics prescribed for UTIs associated with
UTI antibiotic resistance?
H01: There is no statistically significant association between antibiotic resistance
in UTIs and initial antibiotics prescribed.
Ha1: There is a statistically significant association between antibiotic resistance in
UTIs and initial antibiotics prescribed.
Research Question 2: Are continued antibiotics prescribed for UTIs associated
with UTI antibiotic resistance?
H02: There is no statistically significant association between antibiotic resistance
in UTIs and continued antibiotics prescribed.
Ha2: There is a statistically significant association between antibiotic resistance in
UTIs and continued antibiotics prescribed.
Research Question 3: Is the class of antibiotic prescribed for UTIs associated with
UTI antibiotic resistance?
H03: There is no statistically significant association between UTI antibiotic
resistance and class of antibiotic prescribed.
Ha3: There is a statistically significant association between UTI antibiotic
resistance and class of antibiotic prescribed.
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Theoretical Foundation
The theoretical framework for this research study was grounded in Krieger’s
(2001) ecosocial theory. Chapter 2 will contain a more detailed discussion about this
theory. This theory speaks to the criticality of social change and population disease
patterns (Krieger, 2001, p. 668). The importance lies in both the biological and societal
components of change specific to the epidemiology of the responsibility of social
inequality (p. 670). Krieger (2001) produced 4 constructs that are central to Ecosocial
Theory and relate to this dissertation project: “accountability and agency, embodiment,
the cumulative interplay of exposure, susceptibility and resistance, and pathways of
embodiment” (Krieger, 2008). The ecosocial theory (2001) approach works well with the
structural levels of populations and those disease outcomes that can be associated with
multiple population types.
Nature of the Study
A retrospective, observational cohort design methodology was used to describe
the relationship between the incidence of the dependent variable, antimicrobial resistant
UTIs, and the role of the independent variables of initial antibiotics, continued
antibiotics, broad-spectrum antibiotics, narrow-spectrum antibiotics, a combination of
both broad- and narrow-spectrum antibiotics. The variables were utilized to study
nonpregnant American women who were between the ages of 25-44, on Medicaid, and
sought care for UTI symptoms in ambulatory care clinics. The data was abstracted from a
public, national database source known as the National Ambulatory Medical Care Survey
(NAMCS). The database was composed of U.S. national ambulatory setting
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demographic, payment, pharmaceutical, diagnostic, and laboratory, data needed for this
study. The patient data collected in NAMCS was queried for the selection of variables
that met criteria of less than 3 months (initial antibiotics prescribed), and 12 months or
less (for those antibiotics that were continued). After review of baseline data abstracted,
the dependent variable, antibiotic-resistant UTI was queried. Additional independent
variables of broad-spectrum, narrow-spectrum, and broad- and narrow-spectrum
combined antibiotics were queried. Multiple logistic regression was utilized to analyze
patient criteria data.
Definitions
Following are definitions for important terms related to the variables and ideas
discussed in this study:
Aerobic organisms: Organisms that need oxygen to survive (Maier, Anderson, &
Roy, 2015; Murphy & Frick, 2012).
Anaerobic organisms: Organisms that live in direct proximity to the genitourinary
tract and that do not require oxygen to live (Maier, Anderson, & Roy, 2015; Murphy &
Frick, 2012).
Antibiotic resistance: A situation that occurs when the efficacy of a drug used in
the treatment of infections is compromised (Smith et al., 2014; Zur Wiesch, Kouyos,
Engelstadter, Regoes, & Bonhoeffer, 2011).
Antibiotic susceptibility tests: Used to determine what the pathogen will respond
to for antibiotic treatment. Utilized by providers in the treatment of infections. Reported
out as a “MIC” or “minimum inhibitory concentration” (Street & Staros, 2014).
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Broad-spectrum antibiotics: Antibiotics used for empiric therapy when the
microorganism is unknown (Pallett & Hand, 2010).
Clinical classifications: Infections involving a variety of tracts in the human body
(Brede & Shoskes, 2011).
Common commensals: Nonpathogenic microorganisms which have a primary
duty to keep humans healthy (Todar, n.d.).
Narrow-spectrum antibiotic: Antibiotic that can target a specific microorganism
(Pallett & Hand, 2010).
Recurrent UTI: Recurrence with UTIs is typically defined as three or more UTIs
within 12 months, or two or more occurrences within six months (Arnold, Hehn, & Klein,
2016).
Voiding: The human act of urinating. Takes place in the genitourinary tract with
the byproduct being urine (Whiteside et al., 2015; Wolfe & Brubaker, 2015).
Assumptions
In this research, I assumed that the risks for UTI antibiotic resistance in
nonpregnant females, ages 25-44, on Medicaid, and symptomatic with an uncomplicated
UTI regardless of economic status, were not statistically significant among U.S.
ambulatory care settings. According to Garau, Nicolau, Wullt, & Bassetti (2014)
antibiotic consumption and antibiotic resistance directly correlate with one another;
resistance in UTIs after receiving broad-spectrum antibiotics occurs in 55.3 per 100,000
(women) due to inappropriate antibiotic prescribing.
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An additional assumption that was that all diagnoses were made per laboratory
standards, and, licensed health-care providers assessed clinical signs and symptoms.
Laboratory tests are assumed to be governed by the FDA and standard laboratory testing
regulations. Assumptions related to regression analytics that were deployed were that the
DV was dichotomous; the factor level “1” represented the desired outcome. It was
additionally assumed that there would be more than one IV, and that they would be
categorical. It was also assumed that because regression was utilized that a linear
relationship would not be necessary, residuals did not need to be normally distributed,
and homoscedasticity was not needed for each level of IV. Although I did not collect the
data in the national database that I used, a review of the original data collection method
was reviewed and it was assumed that the accuracy of the data was solid.
Scope and Delimitations
Inappropriate management practice for UTIs that includes antibiotic prescribing
practices, accounts for greater than 150 million ambulatory care visits per year. Of the
number of visits per year, more than 13% of all ambulatory care visits provide around 47
million unnecessary prescriptions (The Pew Charitable Trusts, 2016). Clinical guidelines
may not be followed for lower socioeconomic status patients in the treatment of urinary
tract infections. Less costly generic antibiotics, even when known to go against treatment
guidelines, are often prescribed for lower income populations (Denes, Prouzergue,
Ducroix-Roubertou, Aupetit, & Weinbreck, 2012). In addition to antibiotic prescribing,
there may be multiple other factors placing low-economic populations at risk for
antibiotic resistance in the United States. The study focus was to abstract a cohort sample
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of ambulatory care data (physician-patient encounter/visit) from U.S. regions. I had
identified a national survey database to use, the National Ambulatory Medical Care
Survey (NAMCS) (2008- 2012). This database was utilized in the review for risks with
UTI antibiotic management in low-income populations as identified by the independent
variable, Medicaid.
Ambulatory clinic sampling included only non-federally funded offices and did
not include ambulatory visits via phone, house calls, pediatric-specific, or those
ambulatory care offices within an acute care health care facility. Population sampling for
this study included nonpregnant females between the ages of 25-44 on Medicaid with
indicators (diagnosis, medication, reasons for visit, symptoms) that were positive for
urinary tract infection. The CDC and only one other study in 2006 reported that women
between the ages of 25-44 were most likely to become resistant to antibiotic medications
(Butler, Hillier, Roberts, & Dunstan, 2006; CDC, 2011a). Low-income female
populations were represented by using Medicaid payment data available in the national
data sets that indicated insurance type. The categories of females utilized by regional U.S.
studies may not accurately represent all counties within those U.S. regions, therefore, the
delimitations may not represent boundaries that I would have clearly made had I
originally produced the datasets.
Limitations
The data utilized from the national database was intended to be utilized for this
research study. The study data may have been flawed, due to the choice of a retrospective
design. I used a large, national, and public database set that originated in
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the United States. Additionally, though the database used was large, there was no
guarantee that enough subjects would be available with the outcome being investigated.
A prospective approach with a cohort study may be a better choice, however the time and
expense of such a study was not feasible.
Significance
Researchers have indicated that there is a potential relationship between infection
management outcomes and risks for UTI antibiotic resistance related to multiple factors,
including prescribing practices in the inpatient acute setting (i.e., hospital) (Shapiro et al.,
2013). Research published, however, has not adequately supported the critical need for
social change that is focused on UTI clinical management of impoverished nonpregnant
females, such as those on Medicaid, in U.S. ambulatory care settings (Kodner & Gupton,
2010). Urinary tract infections and antibiotic resistance prevention progress have been
confined to pediatric, elderly female, pregnant female populations, or hospital-related
data sources. The literature has not produced quantitative values that can be clinically
correlated and can be applied to prevention effort applications in nonpregnant lowincome female populations in ambulatory care settings. Furthermore, access to the
reliable patient, prescriber, pharmaceutical, laboratory testing and payment data had not
been simultaneously available in ambulatory care.
Factors significant for social change patterns are currently evident. Relevant
epidemiology studies about antibiotic-resistant UTIs and the economic impacts on
specific populations with a high incidence of disease burden related to inappropriate
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treatment greatly impacts federal and state funding. Federal regulators such as the
Centers for Medicare and Medicaid Services (CMS) have already mandated antibiotic
stewardship (ABS) programs in hospitals as part of their conditions of participation
(Centers for Medicare and Medicaid Services [CMS], 2012). CMS states that unless all
efforts to reduce healthcare-acquired infections (HAIs) has been made, including the
implementation of an ABS program, they will not reimburse hospitals for infections after
patients are admitted and in their care. Recommendations to introduce the same ABS
programs in long-term care facilities has additionally been proposed (CMS, 2015). It
would be likely that ambulatory care would be a future target for ABS with CMS.
UTIs and antimicrobial resistance are predominant global health problems that are
associated with all ambulatory care patients (Frieden, 2010). Antibiotic treatment choices
in ambulatory care can greatly impact morbidity and mortality due to antibiotic resistance
(Yang et al., 2013). Community populations are not only associated with antibiotic
resistance in UTIs, but the exposures to inappropriate antibiotic treatment may go
unnoticed. To what extent this damage is causing may not yet be quantifiable. Databases
produced via retrospective collection by health care facilities, universities, state and
federal antibiotic-resistance research are becoming available for trend investigation.
Local hospital infection control or state syndromic surveillance data programs are in
place. These programs apply real-time (active surveillance) data collection techniques to
prevent harm to patients (CMS, 2016).
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Summary
Urinary tract infection epidemiology and the economic burden have changed over
the last few decades. The current climate of antibiotic resistance has become an
emergency. Urinary tract infections rely on the appropriate treatment with antibiotics.
Nonpregnant, low-income female populations, ages 25-44, with UTI symptoms, and
seeking care in ambulatory settings, has been a population in the United States lacking
research studies. Many unknowns have existed that include access to care issues, patient
behaviors, and provider prescribing habits. Those patients who become mismanaged with
antibiotics greatly contribute to the morbidity and mortality of the UTI rate increase
found in community ambulatory care populations.
A review of the literature will be discussed and evaluated in Chapter 2. The
relationship between UTIs and antibiotic resistance and antibiotic management will be
additionally characterized. The literature review will seek to inform readers about the
antibiotic resistance gap in U.S. ambulatory care settings, and nonpregnant, low-income
women with UTIs. Variables such as broad-spectrum and narrow-spectrum antibiotics
were chosen to better understand the utilization and outcome relationships of these drugs
prescribed for UTIs. An evaluation of those gaps in the literature related to antibiotic
resistance patterns in ambulatory care, low-income populations, will be discussed. The
methodology will be revealed in Chapter 3, which will represent my intentions of how
the research will be accomplished. Chapter 3 will report out how this study answered the
questions that I had proposed. Additionally, I will illustrate how the study variables,
ethics, and data will be managed. Finally, the outline of the study results, findings, and
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implications for social change will be covered in Chapters 4 and 5. The final pages of the
dissertation document will include the references and appendices.

20
Chapter 2: Literature Review
Introduction
This literature review was conducted to understand historical and current research
related to UTI antibiotic resistance and how this research is related to antibiotic treatment
in nonpregnant low socioeconomic status females in ambulatory care settings. Chapter 2
includes an overview of historical and contemporary beliefs about UTI antibiotic
resistance and how those models have been applied to low-income populations. I
searched various databases and then reduced my results to include only those studies and
articles that were the most germane to this study.
The chapter will begin with a discussion about ecosocial theory (Krieger, 2008),
which I used to ground this study. The fundamental epidemiological history of UTIs and
the microbiology of antibiotic-resistant UTIs will also be discussed. In the literature
review, I will additionally include data that support an issue of volatility with antibiotic
prescribing for UTIs in ambulatory care settings in low-income female populations in
developing countries, and comparatively, in the United States. Furthermore, this
discussion will include antibiotic stewardship with research-based evidence about
antibiotic utilization and how it can be negatively associated with antibiotic resistance in
UTIs. In the closing segment, I will examine the variables and related literature that I
used in my investigation. I developed my research methodology based on my review of
the literature.
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Literature Search Strategy
I conducted a comprehensive, computerized literature search to obtain abstracts
and published documents relevant via PUBMED, PLoS, Cochrane Database of
Systematic Reviews, Walden University ProQuest Dissertations database, CORE, CDC
database and web pages, The Centers for Medicare and Medicaid database and web
pages, the World Health Organization website, PubMed Central, BioMed Central
Hopkins Medicine website, Pacific Group of e-Journals, Wiley Online Library, American
Society of Microbiology library web site, Agency for Research and Quality database and
website, Whitehouse.gov website, Journal Storage online library, Wisconsin Public
Library system.
The 194 documents chosen were based on the most relevant and recent mainly
between the years’ 2011-2017, except for documents containing historical perspectives,
last-known published findings about my topic, or those years that establish the theory
which I used. A variety of keywords were utilized independently and in combination with
one another in exploring the literature. These included urinary tract infection, Medicaid,
U.S., antibiotic resistance, antibiotic use, low-income female, antibiotic stewardship,
antibiotic prescribing, primary health care, and ambulatory care.
Theoretical Foundation
Krieger (2001) described social change and population health patterns as critical
elements (p. 668) of change that is specific to the responsibility of social inequality in
epidemiology. Within the health care community, the spotlight is on population health,
disease distribution of pathogenic organisms, environmental triggers causing disease, and
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social inequalities which could advance human infectious disease states (Gulis & Fujino,
2015). These focal points are evident in key ecosocial theory (Krieger, 2008). Principal
areas identified by Krieger (2008) are levels, pathways, and power: accountability and
agency, embodiment, the cumulative interplay of exposure, susceptibility and resistance,
and pathways of the embodiment (p. 224). According to Krieger social patterns exist in
all populations and constantly change, however they do not appear to be economic and
political priorities, which result in disparities in unsupported health care endeavors.
Krieger (1994) was the original founder of ecosocial theory (see Figure 1.). This
prototype demonstrates that a change in any of the pathways will alter the life course of
human health. In any population analysis of disease changes, researchers should take into
consideration the causal pathways operating on many diverse levels and spatiotemporal
systems (p. 224) as well as examine historical events to describe the burden in disease
population distribution and inequality patterns as populations have changed over time
(Krieger, 2008).
Krieger (2008) stated that the ecosocial model exposes how proximal and distal
factors change socially (p.233). Proximal factors include those that can be controlled by a
person or by a medical health professional, and distal factors include those factors that
society will have to change (Krieger, 2012). She explained that her theory is an
amplification of the concepts of the gene-environment interaction framework which
posits that individual variations in genetic makeup are extrinsically related to a composite
of disease that has occurred in the human host (Krieger, 1994, 2008; see, also, CDC,
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2016; National Human Genome Research Institute [NHGRI], 2014). Pharmaceutical
interventions that could halt the expression of those genes and which may be biologically
susceptible to disease have been the focus of this type of gene-environment research
(Krieger, 2008). Exposures to cumulative pathogenic, behavioral, environmental, and
physical processes (promote gene expression) are what Krieger (2008) refers to as the
proximal associations that cause disease (p. 233).
The value of the ecosocial theory for this study is to augment the principle
foundations of UTI, antibiotic resistance, and those roles and influential characteristics of
prescribing antibiotics in a non-pregnant, low-income female population. Social
inequality as described by Krieger (2008), was utilized by the authors, Green and
Labonte as a blueprint for their book written about public health policy and pathogenic
economic justice in developing countries and the United States. At the center of the
ecosocial theory are the pathways of population distribution operating within multiple
phases of the infection evolution of UTI. Penders, Stobberingh, Savelkoul, & Wolffs
(2013) investigated how the influence of cultures, geography, and population density may
determine antibiotic susceptibility. Penders et al. (2013) provided evidence indicating a
pathogenic resistance of various organisms that cause UTIs in humans. This study
demonstrates the population distribution relationship posited by Krieger on emerging
antibiotic resistance and how important culture-based studies continue to be even in an
era focused on genetic research.
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Pathways of Ecosocial Theory
Antibiotic resistance can be attributed to the inadequate prescribing of antibiotics,
the innocent patient, or a health-care provider type discrepancy due to lack of availability
in the geographical area of care a patient (Sahoo, Tamhankar, Johansson, & Lundborg,
2010). Population distribution influences the levels segment as well health-care provider
prescribing competency (2013). Additionally, there may be population factors of a
prescription response relationship between low-income female populations and the
buildup of resistance that is even due to minimal antibiotic exposure (2013). Social
constructs that include individual, household, or regional groups may manipulate the
choices found in the pursuit of health treatment. Antibiotic resistance with UTIs may
occur if the “power” and exposure to internal or external forces (i.e.., access to quality
care within a hospital or out in the community) is negatively supported by a remote
geographical region or political environment (McDonnell Norms Group, 2008; Brusch &
Bronze, 2015).
Power of Ecosocial Theory
Krieger (2008) used the diagram to describe conservation ecology of forests and
disease to describe population disease distribution. The diagram was used to detail the
complexity of temporal (old or young forests) and spatial (big or small forests) metrics
seen in ecology (2008). Temporal studies have been conducted on antibiotic-resistant
UTIs encountered in developing countries (Guyomard-Rabinirina et al., 2016). Antibiotic
resistance and UTIs have been found to be like that of a U.S. forest when portrayed as “a
level,” either on an individual or group level, which is central to Krieger’s ecosocial
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theory (p. 224). The impact on spatial issues arise in forests the same as UTIs in humans,
when zoonotic disease such as those that are tickborne (i.e., Babesiosis or Rocky
Mountain Spotted Fever) (LymeDisease.org, 2015) increase in incidence because the size
and location of a forest changes due to excessive commercial logging operations within a
given area (2008). Similarly, UTIs increase in incidence in geographical regions due to
excessive overutilization of antibiotics (Rowe & Manisha, 2013). The distribution of
forest species may also shift negatively in two ways: increase in those species that are
destructive and transmit a dangerous disease to humans and other woodland creatures, or,
forest species whose purpose is to keep other harmful species from emerging or
overpopulation Martins da Costa, Loureiro, & Matos. (2013). Comparatively the same
can be described with antibiotic use and emerging resistance patterns of transmission of
antibiotic resistance in humans as studied by Mamuye, Metaferia, Birhanu, Desta, and
Fantaw (2015) that portray Krieger’s theories as they relate to UTI resistance today.
Levels of Ecosocial Theory
Krieger notes that a population can become quickly eroded because of community
epidemics (2008). She used the example of measles as an argument of how perceptions of
those experiences in a population are rapidly threatened: if measles appeared endemic
within a community (level) the population must exceed a specified number of people
(scale), to identify and understand the cause of the problem as an epidemic before it
becomes endemic (p. 225). When one is considered and not the other (i.e., a level) the
events going on within the population can cripple the community residents if they are not
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recognized (2008). These factors interact to increase the rate of infectious disease and
may lead to community disintegration (p. 224).
Krieger additionally mapped out a hierarchy of distance that is described by
public health as “distal to proximal” as an explanation for epidemic disease (2008, p.
222). Krieger attempted to delete this terminology and replace with “levels, pathways,
and power” (p. 228). Krieger’s use of a map (p. 224) was equal to a hands-on approach,
and supported the arguments she made for how biological and societal disease patterns
originate based on affordability and political agendas. Living standards are associated
with race and social class as she explained which has a tremendous impact on outcomes
with patient and the prescribing of antibiotics due to these agencies regulate who (class of
patient), what (approve types of drugs for use), and how (public health funded or private)
our communities are cared for (2008). For example, if the economic trend in public health
is to cut funding for syphilis surveillance in young female pregnant populations whose
incidence has been rising (CDC, 2015e), initial antibiotic prescribing can impact
community prevalence and the spread of this disease. In chapter 2 of this paper, a
description of the ecological forces and relationships involved in pathogenic responses
related to antibiotic prescribing and ambulatory care patient interactions with health care
that has led to antibiotic resistance is illustrated by Krieger’s’ ecosocial theory.
Literature Review Related to Key Variables and/or Concepts
Antibiotic resistance patterns appear to be progressing in intensity and worldwide
distribution as mankind perseveres in the war on resistant microorganisms (World Health
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Organization [WHO], 2014). It is well understood that antibiotic resistance is purely
guided by utilization (Lee et al., 2014). Daniel et al. (2014) report that in the United
States over 200 million prescriptions are provided to outpatient populations for the
treatment of viral infections alone.
Current State of Antibiotic Resistance
New antibiotic drugs to treat infections need to be developed to keep pace with
resistance (Boucher et al., 2009). One early research initiative to reduce inappropriate
antibiotic utilization analyzed 39 Cochrane studies (Cochrane.org; 2005) and learned that
viral illness will improve on their own if patients are provided with prescriptions and then
asked to delay filling prescriptions for two to three days. By not filling a prescription, the
percent chance of antibiotic resistance is reduced to zero (Bartlett, Gilberg, & Spellberg,
2013). Regardless of how perfectly this is understood, inappropriate utilization continues.
In the United States, health-care providers make poor choices in the prescribing of
antibiotics 50% of the time (CDC, 2013a). Over the last century, it had been possible to
control antibiotic prescribing for infections and observe susceptibility without the
conferral of antimicrobial resistance (Davies & Davies, 2010). Today, antibiotic
resistance patterns have accelerated (Hawkey, 2008). The treatment of infections without
resistance is no longer under our human control (President’s Council of Advisors on
Science and Technology [PCAST], 2014). The effects now span to all classes of
antibiotics with many pathogenic isolates, at local, national, and global levels (2010).
Efforts to protect those classes of antibiotics that produce rare resistance has become a
worldwide priority (Carlet et al., 2012; 2014).
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Epidemiology of Antibiotic Resistance
Annually, antibiotic resistance distribution rates associated with morbidity and
mortality are published in the United States, the CDC (Centers for Disease Control &
Prevention [CDC], 2013b) shows that approximately 23 million deaths occur annually as
a direct result of infections that are resistant to one or more classes of antibiotics.
Children in the 1-5-year-old age range have been identified in the United States as one
population with antibiotic resistance increasing, however the variability in geographic
area, methods of surveillance and data collection, and the identification of risk factors as
well as prevalence will need to be researched further (Rush University Medical Center
[RUMC], 2014; Bryce et al., 2016).
Current UTI prevalence. The prevalence of antibiotic-resistant UTIs in pregnant
women, the most common complication in pregnancy, is also increasing. Rizvi et al.
(2011) studied 4,290 urine samples from pregnant females and identified prevalence rates
of 78% for asymptomatic bacteriuria (n=3210) and 25.2% (n=1080) with symptomatic
UTIs. Pregnant females, unlike nonpregnant females in the United States, regardless of
socioeconomic status, are managed with antibiotic medications for both asymptomatic
bacteriuria and symptomatic due to the known high morbidity caused by untreated UTIs
(2011). The prevalence rate of UTIs in the United States in nonpregnant females who
seek care in ambulatory care settings has not been published other than to mention that
85% of UTIs occur in both the pregnant and nonpregnant female populations. Prevalence
rates in ambulatory care settings for nonpregnant females who are dependent on
assistance with insurance, such as Medicaid, for UTIs, to date, has not been published.
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Pregnant females, unlike nonpregnant females, have had regular infusions of unrestricted
grant funding for studies to support protocols and further research studies related to
antibiotic resistance (Martinez de Tejada, 2014). Nearly 2 million people in the adult U.S.
population (p. 11) have died or will have died of serious complications because of
antibiotic resistance and were treated by drugs that were designed specifically to
eliminate harmful pathogens (Food & Drug Administration [FDA], 2011; Fair & Tor,
2014). The declining effectiveness of antibiotics due to negative outcomes such as
mortality, raise concern over the costs that produce widespread economic burden
(Gandra, Barter & Laxminarayan, 2014).
Economic Burden of Antibiotic Resistance
The annual economic burden estimated at over 60 billion dollars indicates that of
this amount, 35 billion dollars in productivity costs are lost that are directly attributable to
antibiotic resistance in the United States (Centers for Disease Control & Prevention
[CDC], 2013b; Network for Excellence in Health Innovations [NEHI], 2013). Although it
is a challenge to measure the economic burden of antibiotic resistance it is projected that
by the year 2050 over 100 trillion dollars and 10 million deaths will contribute to
economic loss associated with this problem (O'Neill, 2014). A macroeconomic approach
must be carried out in any future studies per Gandra et al. (2014) to quantify the true
economic influences of antibiotic resistance. Currently, in the United States there are
substantial financial and clinical burdens related to several pathogens causing dangerous
levels of resistance (Centers for Disease Control & Prevention [CDC], 2015c).
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Antibiotic Utilization
Multiple factors today impair antibiotic treatment and lead to antibiotic resistance,
(CDC, 2013a, p. 11). In ambulatory care, the most common antibiotics used are those
prescribed for seasonal viral medical conditions caused by pathogens that do not require
antibiotic treatment (Shapiro et al., 2013). Examples of medical conditions that do not
need antibiotics are cold and Flu viruses (Centers for Disease Control & Prevention
[CDC], 2015d). There are times when these viruses cause an illness that exacerbates
another underlying medical disease process already in progress (Singanayagam, Joshi,
Mallia, & Johnston, 2012). The lowered resistance due to viruses combined with chronic
disease processes can trigger or further promote bacterial growth in an organ’s location of
chronic disease (Kurai, Saraya, Ishii, & Takizawa, 2013; Yamaya, 2012). For example,
an individual with Chronic Obstructive Pulmonary Disease (COPD), a chronic
respiratory disease, acquires Influenza (a respiratory illness) and may be more susceptible
to bacterial pneumonia (a different respiratory illness).
Broad-spectrum antibiotics. Antibiotics that cover many different pathogens
utilized by ambulatory care providers are known as Broad-Spectrum antibiotics (Shapiro
et al., 2013). Two classes of broad-spectrum antibiotics, macrolides, and
fluoroquinolones, are used the most. Studies to understand our current state of antibiotic
resistance related to the misuse in antibiotic selection type is needed (Shapiro, Pavia, &
Shah, 2011; Walker, 2013).
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Epidemiologically Significant Pathogen Emergence
The CDC has compiled a list of hazardous antibiotic-resistant pathogens that
often accompany inappropriate prescribing of antibiotics; these pathogens represent an
“urgent, serious, or concerning” threat and are quickly progressing antibiotic resistance
patterns (Golkar, Bagasra, & Pace, 2014; CDC, 2015c).
Threat levels defined. An “urgent” threat is the most serious due to that there is a
high risk for widespread antibiotic resistance to occur. A “serious” threat describes
behaviors in pathogens identified that may worsen if they are not closely monitored.
Finally, a “concerning” threat may be stated as a low-risk because the choices for
antibiotics are still many, however, severe illness can also still occur. These threats were
defined by a level of harm thought to be caused by the pathogens identified and intended
to be utilized for prevention purposes with epidemiology surveillance programs (CDC,
2015c).
Urgent threats. Larger urban populations produce antibiotic-resistant pathogens
that would be considered “urgent” on the CDC threat list. Since the year 2000, key
“urgent” pathogens known as Carbapenem-resistant Enterobacteriaceae (CRE) or
Carbapenem-resistant Klebsiella pneumoniae (CRKP) have increased from less than 1%
to greater than 12% in larger urban regions (Satlin, Jenkins, & Walsh, 2014). It is not
unusual to find a 50% mortality rate (p. 1) of infection in major medical centers in large
urban areas where complicated procedures such as solid organ transplant (SOT) are
performed. Facilities that provide SOT have been reporting CRKP infection incidence
rates at or greater than 10% (Satlin et al., 2014, p. 2).
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In a metanalysis of liver transplant patients, the mortality incidence was five-fold
higher in those patients with CRKP infections identified postoperatively in a hospital
setting (Kalpoe et al., 2012). In contrast, a different study discussed that healthcare
personnel working in an ambulatory setting of one western U.S. region took a model
approach to carbapenem-resistance prevention to prove that these resistant pathogens
could be decreased (Lee et al., 2016). The authors applied the principles provided in the
CDC carbapenem resistance toolkit to simulate a decrease in carbapenem-resistant
pathogens. The health care workers conducting the study had identified that by the year
2025 carbapenem-resistant pathogens would grow to endemic proportions, however by
utilizing this toolkit, they were able to prove a 50% reduction in incidence rates in the
population (Lee et al., 2016).
Serious threats. Other important antibiotic-resistant pathogens in addition to
carbapenem-resistant pathogens have indicated a slow upward trend developing in
community-acquired antibiotic resistance in various regions in the U.S. pathogens include
Vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas
aeruginosa (MDR-PA), Imipenem-resistant Acinetobacter baumannii (CR-Ab), and
resistant Escherichia coli and Klebsiella pneumonia, both of which are known as
“Extended Spectrum Beta Lactamase” (ESBLs) due to that they are resistant to third
generation cephalosporins (aka, Beta Lactam antibiotics) (Lee et al., 2013). VRE is often
found in immunocompromised patients if it is a true infection, however, there is a high
prevalence of carriage in the community (Byappanahalli, Nevers, Korajkic, Staley, &
Harwood, 2012). Methicillin-resistant Staphylococcus aureus (MRSA) was said to have
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been increasing in incidence and prevalence in the community over the last decade
(Mekviwattanawong, Srifuengfung, Chokepaibulkit, Lohsiriwat, Thamlikitkul, 2006). In
2010, however, a newer study by the CDC was released that indicated a decrease in
community MRSA (Kallen et al., 2010).
Concerning threats. In many geographic regions in the United States, MRSA is
now considered endemic (David & Daum, 2010). Endemicity does not lessen the
virulence of this pathogen, however. Many of those pathogens previously discussed are
carried on a person’s body as normal flora (Borchert et al., 2008). Lowering of the
immune status may predispose a person to illness as healthy humans are able to coexist
with their normal flora, even pathogens (Harvard Health Publications, 2015). Pathogens,
however, rapidly learn and adapt faster than antibiotics are produced (Childress, 2013).
Strategic deployment of effective and sustainable activities with antibiotic stewardship
using education as a multidisciplinary tool, are necessary (Azevedo, Capela, Baltazar,
2013)
Antibiotic Stewardship
According to the Association for Professionals in Infection Control and
Epidemiology (APIC, 2012) antimicrobial stewardship is “a coordinated program that
promotes the appropriate use of antimicrobials (including antibiotics), improves patient
outcomes, reduces microbial resistance, and decreases in the spread of infections caused
by multidrug-resistant organisms.” The consequential warnings of future inappropriate
utilization of antibiotics were hinted at in 1945 by Sir Alexander Fleming during his
Nobel Prize acceptance speech (Fleming, 1945). The Center for Disease Dynamics,
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Economics & Policy (CDDEP, 2014) released global data for the third millenium that
substantiates Dr. Fleming’s long-ago warning indicating that there has indeed been more
than a 35% increase in antibiotic utilization between 2000 and 2010.
Antibiotic stewardship priorities in the United States. The two leading
concerns that present a challenge for healthcare-providers today as noted by Bjorkman,
Berg, Viberg, and Lundborg (2013) are antibiotic resistance and UTIs. The United States
is the third largest consumer of antibiotic prescriptions as evidenced by an unprecedented
utilization increase. Hicks et al (2015) reported that 182.7 million prescriptions were
provided to adult patients, or 789 prescriptions per 1000 adults according to U.S.
ambulatory data from 2011 (p. 1311). Narrow-spectrum antibiotics (macrolides and
penicillin’s) were prescribed for 41%, and broad-spectrum antibiotics prescribed for 31%,
of females, >20 years of age, in ambulatory care settings (p. 1313). This represented a
rate in antibiotic prescribing in females >20, of 1102.2 (prescriptions per 1000 persons)
with an adjusted odds ratio (OR) of 2.4 (confidence interval (CI) 1.9-2.9) (Hicks et al.,
2015, p. 1313). By 2013, broad-spectrum antibiotic prescribing in adults increased from
24% to 48% (Lee et al., 2014). Social determinants (2015, p. 1314) were recommended
for future research.
The U.S. female population literature gap. The management of urinary tract
infections (UTIs) caused by antibiotic resistance in female populations is a challenging
responsibility for any healthcare-provider (Pronovost, 2013). The influence on health care
management in female populations begins before health problems occur (DeMilto &
Nakashian, 2016). U.S. studies to date related to UTIs and antibiotic utilization have only
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focused on pregnant female populations and the management of UTIs. This has been
primarily due to the elevated risk of harm to the unborn child. Influential studies in the
U.S. on social determinants such as income and gender and the role that these play in
antibiotic resistance are absent.
Studies conducted in the United States with antibiotic prescribing have
determined that females are a high risk for resistant UTIs (Lawal, 2012; Vasudevan,
2014). This evidence is directly related to ambulatory care visits for UTI symptoms and
higher antibiotic utilization rates with both narrow and broad-spectrum antibiotics.
Females comprise 84.5% of the 3 million patients in the United States with UTI
symptoms as their primary complaint and are a high risk for UTIs (Thoureen, Scott, &
Best, 2015). The rate of uncomplicated UTIs in females between the ages of 18-49 in the
United States who receive antibiotic treatment is 28.2 percent for every 10,000 females
(Lawal, 2012). The current gap in the literature is to understand how two classes of
antibiotics (narrow and broad-spectrum) are prescribed to nonpregnant females with UTI
symptoms in ambulatory care settings and the role in antibiotic-resistant UTIs. Without
research studies conducted at home in the United States, barriers will remain unknown
and funding cannot be substantiated. Unfortunately, economic study evidence outside of
the U.S. is not comparable.
UTI-specific antibiotic stewardship. Antibiotic stewardship in UTIs has become
increasingly important. E. coli bacteria is the cause of 80% of every 7 million human
UTIs diagnosed in the ambulatory care setting (Yadav, Singh, Kumar, Katewa, &
Kumari, 2014; E. coli 131, a highly resistant strain of E. coli bacteria, is said to be
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causing a “stealth pandemic” (Brusch, 2016). Recurrence in UTIs is usually related to the
same pathogen that caused the initial infection. Antibiotic resistance and the overuse of
broad-spectrum antibiotics have been noted as primary contributors in the escalation of
antibiotic resistance and recurrence of UTIs outside of the United States (Zowawi et al.,
2015). Mazulli (2012) documented that a relapse in a UTI will occur in 25% of women
within 6 months of treatment, therefore working towards a cure while limiting unintended
consequences such as infection recurrence is the primary goal of antibiotic stewardship
(Abbo & Hooten, 2014).
Bacterial strain resistance according to Abbo and Hooten (2014) that have been
due to E. coli bacteria, prompted researchers to begin really studying antibiotic resistance
and stewardship in ambulatory care settings just after the turn of the 21st century. It has
been well documented that resistant endemic strains of bacteria and viruses are carried
into the hospital setting from the community (Sydnor & Perl, 2011); the communityacquired resistant strain of Staphylococcus aureus known as “CA-MRSA” is now present
in hospital infections (p. 148). In 2015, a report to the President of the United States was
provided to the White House that provided evidence of dire outcomes if antibiotic
stewardship was not made a priority (President’s Council of Advisors on Science and
Technology [PCAST], 2015). Ambulatory care has made great strides in the stewardship
of appropriate prescribing practices as evidenced by studies published recently in the
literature (Hicks et al., 2015). It is of great importance as antibiotic stewardship practices
advance in ambulatory settings, especially with UTI treatment, that prescribing practices
are continually re-evaluated at regular intervals (Abbo & Hooten, 2014).

37
Health-care providers utilize laboratory tests in the diagnosis, treatment, and
continuing management of any illness. According to Bhavsar (2015), clinical significance
is not often found among the many urinary cultures that a laboratory receives for testing.
This is usually because of contamination that occurs during collection or other factors
related to storage and transportation of urine specimens (Bekeris, Jones, Walsh, &
Wagar, 2008). It is for these reasons that signs and symptoms must be considered and
prescribing choices will need to be based solely on these details (Pallett & Hand, 2010).
Unfortunately, this leads to prescribing antibiotics in a blind fashion, or “empirically.”
Prescribing antibiotics empirically is a delicate act of balance that the healthcareprovider must go through to decide on the best course of treatment for their patient; this
must be carried out rationally and thoughtfully. Choosing an antibiotic will need to be
individualized for the patient and the geographic prescribing region. Consideration taken
in advance for known epidemiologically significant pathogens in the area, especially
those on the urgent or serious list of resistances (CDC, 2015c) may be the difference
between curing illness and increasing the likelihood of recurrence. (Ventola, 2015).
Patient factors to consider would be related to allergies, compliance with medications (if
known), and costs that may be associated with treatment.
Patients having a lower income status may not have the financial means to pay for
more than basic testing or generic medications (Farfan-Portet, Van de Voorde, Vijens, &
Stichele, 2012). Recurrent infections may be costlier due to that they may need longer
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treatment or medications that are not available on a generic formulary list. Patients with a
lower income may also add to the already-present antibiotic stewardship challenges that a
healthcare-provider has in treating UTIs that are not associated with monetary costs.
Current infection status, for example, may be unknown. The health-care provider may
not get an accurate history and unable to discern whether the patient had already been
treated for an infection. Poverty is also a known driving factor in medication sharing,
hoarding of medications, and resorting to self-directed treatment (Planta, 2007). In
today’s world, the internet is a place that can be unregulated when it comes to
medications, which comes with its own challenges for antibiotic stewardship. Anyone
can order almost any medication online and get it shipped directly to them, often without
a prescription (Orizio, Merla, Schulz, & Gelatti, 2011). Computers may not even be
necessary if you have a smartphone with an internet connection. If you do not have a
phone with this technology, the public library has computers that are free for community
residents to use (Gates Foundation, 2005). The public may be naïve about the lack of
quality control with these medications available through the internet (World Health
Organization [WHO], 2011).
Other avenues to gain prescriptions that are not regulated are also available and
are not difficult to come by if you have a passport and like to travel. In contrast, before
the last two decades, internet services were not available and travel outside of the United
States was not commonplace for the everyday resident. Cheap air travel today has
afforded many the opportunity to travel to countries outside of the United States which
have pharmacies that carry all types of medications including many antibiotics that do
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not require prescriptions signed by a provider (Lior & Cots, 2009). The real issue,
however, lies in the absence of quality control measures. Medications that have not been
checked for quality may pose further health and safety risks (WHO, 2011). According to
a Princeton University (1995) publication, in using unregulated antibiotics, old
antibiotics, or someone else’s antibiotics, a person will be compounding the already
difficult task that any licensed healthcare-provider has in trying to cure an oftenuncomplicated illness like a UTI.
Past and Present Dynamics with UTI Epidemiology
The historical literature reviewed indicates that prior to 1980, UTI antibiotic
resistance was being seen in almost every antibiotic (Bartlett et al., 2011). Resistance
patterns vary from region to region. Surveillance data that is normally performed at the
local level (Masterton, 2008), to include state syndromic surveillance data captured via
emergency departments, is often relied upon to determine antibiotic susceptibility in the
community since there can be a large variance seen from region to region. Broadspectrum antibiotics are known to be the most corrupt out of all the antibiotics; their
utilization is greater, therefore, resistant pathogens are also increased (Garau et al., 2014).
Of the broad-spectrum antibiotic choices available today, several disturb normal flora,
creating an environment for disease and resistant pathogens to flourish (Odonkor &
Addo, 2011) and are known to have a higher risk for resistance such as sulfonamides,
fluoroquinolones, and cephalosporins (Fair & Tor, 2014). The pathogen most likely to be
the cause of up to 90% of UTIs in females are Escherichia coli (Gupta, Hooton, &
Stamm, 2001; Ulleryd, 2003). Empiric selection of antibiotics has become more
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important in recent times due to the increase in antibiotic resistance in E. coli. (2001).
While previous surveillance studies may have identified significant differences in the
frequency of susceptibility to common urinary anti-infectives between isolates collected
from male and female patients, currently this has not been consistently observed (LagaceWiens et al., 2011). This quantitative study’s aim was to investigate the temporal
progression of antibiotic resistance incidence in UTIs and consider essential data details
like the differences in economic status.
Summary and Conclusions
This chapter provided a literature review of historical, epidemiological, and
fundamental knowledge concerning UTIs and antibiotic resistance. Empiric prescribing
of broad-spectrum/narrow-spectrum antibiotics were also described which included those
elements for antibiotic decision-making by the healthcare-provider. Clearly visible in the
literature was the obvious contributory role of antibiotic exposure to urinary traction
infection resistance. Additionally, the sample population attributes, independent and
dependent variables, and suspected link of an increase in recurrent UTIs was exposed by
the literature review. Unfortunately, studies that could be utilized to statistically
investigate and reinforce an association between antibiotic resistance and urinary tract
infections due to those risks such as health care coverage type, in nonpregnant lowincome female populations in U.S. ambulatory care settings, came up short without
appropriate comparison of literature, or, did not exist at all. However, those documents in
the literature reviewed could support the hypotheses and analysis of the dependent and
independent variables. I will include a simplified description of data details, including
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variables, to be assembled. The method and design proposed for this research study will
be examined in Chapter 3.
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Chapter 3: Research Method
Researchers with the NAMCS began data collection in 1973, and, since 1989,
have been collecting survey data annually in ambulatory physician clinics in the United
States. I analyzed these survey data to evaluate risk factors for antibiotic resistance, with
a specific focus on exposures to health care insurance coverage in low-income
nonpregnant female populations with UTI symptoms who seek care in the ambulatory
setting. Study subjects were drawn from 112 primary sampling units (PSUs) from 50
states in the United States and the District of Columbia. I retrospectively reviewed the
survey data to identify U.S. nonpregnant female populations who had sought care for UTI
symptoms in ambulatory clinics and had health care coverage with Medicaid. In Chapter
3, I describe the research methodology I used. I provide an overview of my research
design, population, and sampling procedures; a description of study variables and my
plan for data analysis; and discussion of threats to validity and ethical concerns.
Research Design and Rationale
In this study, I retrospectively illustrated and analyzed NAMCS observational
data for a cohort of ambulatory care clinic visits by U.S. women. The design facilitated
discovery of important variables that were confounding factors whose relationships to the
exposures were in question.
Study Design Selection
The design of a retrospective observational cohort study design was used to
estimate antibiotic resistance in UTIs at the group level; ecological bias issues were
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considered. I chose a retrospective approach based on the availability of variables during
the original survey period chosen when antibiotic resistance is thought to occur (Al-Badir
& Al-Shaikh, 2013). The NAMCS survey data available for public use were chosen from
the years 2008-2012. The source population appropriate for this design was a cohort from
U.S. ambulatory care nonpregnant female patient visits whose risk for UTI antibiotic
resistance was due to exposure to poverty. Medicaid, a type of health care coverage was
used to identify those with a lower income status. Risk adjustments were based on the
NAMCS data collected from 2008-2012. The study design considered time, dose, and
nature in the assignment of risks associated with UTI antibiotic resistance in the cohort
chosen. The pursuit of a retrospective observational study seemed like a logical way to
conduct this study investigation.
Design advantages. The advantage to using a retrospective observational cohort
study is that observer bias is lessened and multiple relationships to a single exposure can
be investigated (Mann, 2003). Original survey data had already been procured by
NAMCS, therefore, this design appeared to be the most efficient, least time-consuming,
and most accurate analysis (see Euser, Zoccali, Jager, & Dekker, 2009; Huston & Naylor,
1996). UTIs do not appear to be rare in the population of interest, low-income females.
The observational design of this study allowed for access to health care survey
information without having to conduct interviews; exposure association assumptions
were made without direct observation (Carlson & Morrison, 2009). The data collection
methodology for this study was completed using a standard method which allowed for
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comparison over time and generalization using multiple regions of the United States for
analysis (see Mann, 2003).
Study design disadvantages. Although bias is lessened with this study design,
disadvantages in using this type of design are that causal relationships may be difficult to
establish with more than one factor in use. Bias and confounding are difficult to control
for (University of Portsmouth, 2012). The data I used were not designed specifically for
my study which could have put me at a disadvantage. However, the survey data provided
by NAMCS contained enough details for analysis. correctly for my examination. For
example, it could have been difficult to identify a group to compare for exposure without
specific age groups identified by NAMCS. However, this was not the case.
Methodology
Population and Sampling
A secondary database source was utilized for my study which included
information on the research design. I used the NAMCS database, a national sampling
survey. The survey was designed and managed by the Ambulatory and Hospital Care
Statistics branch of the CDC (2011). The sampling frame for 2008-2012 was composed
of all nonfederal ambulatory care clinic visits to physician offices (excluding radiologists,
pathologists, and anesthesiologists) whose provider data were maintained within the
American Medical Association and American Osteopathic Association master file
databases. The U.S. Census Bureau staff acted on behalf of the CDC in the collection of
clinic visit data for the national ambulatory survey (Hall, Schwartzman, Zhang, & Liu,
2017).
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Sampling procedures. Sample visit data collected for NAMCS included
physician and patient statistics, as well as patient visit characteristics. A three-stage
process of sampling was conducted. Primary sampling units, or, “PSU’s,” were selected
by NAMCS surveyors which consisted of first, 112 U.S. geographical regions, second,
the selection of physician ambulatory clinics, and third, the selection of patient visits
(CDC, 2011). Data processing and medical coding were performed by SRA International,
Inc., Durham, North Carolina. Quality assurance and control procedures were performed
with 10 percent of patient records used as a sample and were entered and coded
individually (2011). Sample data formed standard errors and national estimates after
estimated visit samples were weighted (2011). The CDC describes their calculations for
each visit as complicated and had many stages designed for weight computations which
reduced bias by inflating survey data or weighted national estimates (2001). A four-part
activity was undergone for visit weighting that included “inflation by reciprocals of
selection probabilities, adjustment for nonresponse, population ratio adjustments, and
weight smoothing” (CDC, 2011). The complexity of their design was further explained
by their use of Taylor approximations in SUDAAN to estimate the variability in sampling
(2001).
Study Population Sample
The target source population for this research project consisted of National
Ambulatory Medical Care Survey (NAMCS) patient visits occurring between 2008 and
2012. Female patients, that visited U.S. ambulatory care clinics comprised 57% of the
total patient visits in the NAMCS studies between years’ 2008-2012 (N=199,456). The
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patient visit sample population that met inclusion criteria as high risk for developing
antibiotic-resistant UTIs per the literature, were nonpregnant females, age 25-44,
reporting to ambulatory care clinics for UTI symptoms, and on Medicaid (N=51).
Sample methodology. All demographic and clinical patient visit data were
reviewed for potential proximal and distal risk factors for exposure to potential negative
outcomes. Proximal factors as explained by Krieger (2008) are those behavioral,
biological, psychological, and physical processes that perform on or near the body and
are controlled at an individual level. Distal risk factors, or those factors shaping a
person’s exposure, may be stated as social determinants.
Proximal risk factors for exposure and study inclusions. First, risk factors for
proximal exposure were identified from the secondary sample frame population visit data
that included the following variables (N=51): pregnancy status (nonpregnant), as
evidenced by the NAMCS 2012 code “Pregnant” (2012) or ICD9 code classifications
referent to a state of pregnancy for years’ 2008-2011; sex (female) as evidenced by
“female;” age (25-44) as evidenced by “age 25-44;” “Diag1, 2, or 3” with ICD9 diagnosis
codes of “5990” (urinary tract infection site not specified), or “5950” (acute cystitis), or
“59080” (Pyelonephritis) (NAMCS, 2008; NAMCS, 2009, NAMCS, 2010, NAMCS,
2011, NAMCS, 2012). Antibiotic prescribing methods by the provider, as a proximal
factor for exposure, was identified at three levels (broad-spectrum antibiotics, narrowspectrum antibiotics, and the broad/narrow-spectrum combination of antibiotics). United
States population identification for the purposes of this study may include “American” as
a surrogate for U.S. nationality.
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Distal risk factors for exposure and study inclusion. Distal factors structure a
person’s exposure and in health care social determinants are influential, according to
Krieger (2008). This study reviewed the secondary study data for exposure risk and found
that a social determinant was available to include as an indicator of income status:
Medicaid (N=51). Additionally, risk exposure related to evidence-based antibiotic
treatment guidelines for uncomplicated and complicated UTIs in nonpregnant
populations (National Institute for Health Care and Excellence [NICE], 2016)
recommend a three-day course of antibiotics for uncomplicated UTIs and greater than
three days if the UTI is complicated (recurrence, pyelonephritis). Antibiotic treatment
status as a risk factor was available at two levels: initial, or continued.
Sample exclusions. Those patient care visits and populations excluded in this
study were phone visits, house calls, emergency department visits, federal facility visits,
elderly adult, males, pregnant females, females under the age of 25 or over 44, pediatric,
and hospitalized patient populations. Patient comorbidities were also not considered for
risk now due to too many overall possibilities that would increase study length of time
requirements and may have had an overall effect on the design choice. Those patients
who were uninsured were additionally not included due to that the reason for not having
insurance could not be ascertained. The NAMCS code for type of problem (new, chronic,
post-op, etc.…), “MAJOR,” was also not utilized due to that the “reason for visit”
(NAMCS, 2012) (RSV) had several choices, which did not correspond well with the type
of problem.
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Pregnant female-visit exclusion rationale. In chapter two it was noted that
pregnant female UTI incidence was only slightly higher than non-pregnant female UTI
incidence with variations between 2% and 13% (Lumbiganon, Laopaiboon, &
Thinkhamrop, 2010; Matuszkiewicz-Rowynska, Malyszko, & Wieliczko, 2015). For this
study, pregnant female patient visits were not included in the cohort age range selected
because pregnant women are a much higher risk for complications due to their state of
carrying an unborn child, and unlike nonpregnant females in the general population,
pregnant females are screened for bacteriuria because of the high risk of pyelonephritis as
a complication (August & DeRosa, 2012; Prakash & Saxena, 2013). All UTIs in
pregnancy are considered complicated and normally only treated by a specialty healthcare provider. (Johnson & Kim, 2015).
Cohort sample size. Logistic regression tables for sample size were reviewed to
estimate the minimum sample size required to confidently accept the results of the
analysis (Hsieh, 1989). The literature indicated that the probability of an antibioticresistant UTI diagnosis within 6 months was 2, and one year after treatment was 3 (AlBadir & Al-Shaikh, 2013; Dason, Dason, & Kapoor, 2010). Countries other than the
United States have begun publishing overall antibiotic resistance rates for various
regions. Historically, the United States. had not published overall antibiotic resistance
rates, though they have reported individual pathogen resistance rates. In 2011, this
changed, and results produced from a survey conducted by the Infectious Disease Society
of America Emerging Infections Network indicated that around “60% of participants had
seen a pan-resistant, untreatable bacterial infection within the prior year” (Hersh,
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Beekmann, Polgreen, Zaoutis, & Newland, 2009). For this study, which was based on a
very large national survey, comprised of office visits, and from this, predominant factors
already available as variables in the NAMCS data set were utilized to identify the sample
frame that included exposures and non-exposures. These variables included “SEX”
(1=Female); “PAYMCAID” (1= Medicaid as payment type); “PREGNANT” (2=
Nonpregnant) (available only in 2012); “DIAG 1, 2, 3” (ICD 9 Codes indicating an upper
or lower urinary tract infection), and, “AGE” (ages 25-44) (National Bureau of Economic
Research [NBER], n.d.). From this overall exposure/non-exposure data, a simple random
sample was calculated electronically for an appropriate sample size (National Statistical
Service, n.d.). To find an odds ratio of 2.0 for a patient exhibiting UTI symptoms and
having a positive UTI diagnosis, a one-tailed test was used with one standard deviation
above the mean, a significance level of α= 0.05, confidence level of 95%, confidence
interval of 0.05 (upper 0.55, lower 0.45), standard error of 0.03, relative standard error of
5.10, and a power of 80%, indicating that a minimum of 42 cases were needed; 45 cases
were randomly included for the final study sample.
Variable Descriptions
Variables collected for measurement purposes resulted from each ambulatory care
visit captured by the national NAMCS survey data set between 2008 and 2012. Each visit
was analyzed for possible associations related to the variables chosen for this study. The
dependent and independent variable definitions and measurements are stated in Tables 13, after the descriptions of all study variables.
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Dependent variable. The primary dependent variable (DV) identified was UTI
antibiotic resistance (see Table 1). The variable was defined by ICD9 Diagnosis codes
that included “5990 (UTI), 59780 (URETHRITIS), 5999 (URINARY DISORDER NOS),
59080 (PYLONEPHRITIS), 5950 (ACUTE CYSTITIS), 5959 (CYSTITIS).
Additionally, the variable was defined by utilizing the already present NAMCS
codebooks available; “RFV” (reason for visit), included signs and symptoms of a UTI
(NBER, n.d.). UTI signs and symptoms may be one of the following codes per NAMCS
codebook (NBER, n.d.), “Reason for Visit Tabular Classification:” 1675 (urinary tract
infection), 1660 (urinary dysfunction), 1650 (painful urination), 1910.1 (low back pain),
1905 (back symptoms), 1545 (abdominal pain), 2705 (UTI pyelonephritis), 1665.1 &
1665.2 (bladder pain and infection), 1645.0 (urinary urgency and frequency), 1545.2 (low
abdominal or quadrant/inguinal pain), 1775 (pelvic pain), 10552 (flank pain) (2012),
(AND) at LEAST ONE Antibiotic was Prescribed: “ABXRX: 1=Yes, 0=No, (AND) at
LEAST ONE antibiotic must be new or continued.
Measurement of the DV. The dependent variable in question was measured by
whether it met definition criteria (1=UTI Resistance Criteria Met, and, (0=UTI
Resistance Criteria Not Met).
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Table 1
Summary of Dependent Variable
Variable type
Dependent

Variable
UTI
Antibiotic
Resistance

Variable
definition
1. An ICD9
Diagnosis
code of
“5990, 59780,
5999, 59080,
5939,5950,
5959.”

and/or
2. RFV (reason
for visit)
includes signs
and symptoms
of a UTI. UTI
signs and
symptoms may
be one of the
codes per
NAMCS
codebook:
“Reason for
Visit Tabular
Classification.”
See Table 2 for
NAMCS codes

Coded value
UAR

Measure

Measure

“1” = UTI
Resistance
Criteria Met

“0” = UTI
Resistance
Criteria Not
Met
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Table 2
NAMCS Codes: Reason for Tabular Classification
Code

Code description

1545

Abdominal pain

1545.2

Lower abdominal or quadrant/inguinal pain

1645.0

Urinary urgency and frequency

1650

Painful urination

1660

Urinary dysfunction

1665.1 & 1665.2

Bladder pain and infection

1675

Urinary tract infection

1775

Pelvic pain

1905

Back symptoms

1910.1

Low back pain

2705

UTI pyelonephritis

Note. The NAMCS codes, reasons for tabular classification, have been extracted from the NAMCS
microdata file documentation for NAMCS survey years’ 2008-2012.

Independent variables. The independent variables (IV) chosen were relevant to
the study questions and hypotheses stated.
IV initial antibiotics prescribed. The first IV, “initial antibiotics prescribed,” was
coded as “INABXRX.” This variable was defined as a new patient visit related to UTI
signs/symptoms with onset less than 3 months, (AND) one or more initial antibiotics
prescribed. See Table 2.
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Measurement of INABXRX. INABXRX was measured by “1=Initial Antibiotics
Prescribed, and, 0=Initial Antibiotics Not Prescribed.”
IV continued antibiotics prescribed. The second IV, “continued antibiotics
prescribed,” coded as “CONABXRX.” CONABXRX was defined as a recurrent visit, by
a referral or previously seen by a primary provider related to UTI signs/symptoms with
onset less than 12 months, (AND) one or more antibiotics prescribed are continued. See
Table 3.
Measurement of CONABXRX. CONABXRX was measured as “1=Continued
Antibiotics Prescribed, and, 0=Continued Antibiotics Not Prescribed.
IV broad-spectrum antibiotics. The third IV, and first antibiotic class of IV’s of
“broad-spectrum antibiotics,” coded as “BS,” was defined as a class of antibiotics that
covers a variety of different pathogens in the treatment of an infection. Antibiotics
selected for this study, including NAMCS codes (NBER, n.d.) were Sulfamethoxazole
(29840), Metronidazole (19233), Levofloxacin/Levaquin (97163, 97045),
Tindamycin/Tindazole (7212), Ciprofloxacin (92111/6839), Besifloxacin (11096),
Ceftriaxone/Rocephin (91069), Azithromycin (93214), Keflex/Cephalexin (16475),
Ampicillin (1685), Cefpodoxime (93166/d0095), Fluoroquinolones (8574), Doxycycline
(10355), Augmentin/Amoxicillin-Clavulanate (60115), and Ceftizoxime (d00010)
(NAMCS, 2012). See Table 3.
Measurement of BS. BS was measured “1=Broad-Spectrum Antibiotics
Prescribed, and, 0=Broad-Spectrum Antibiotics Not Prescribed.”
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IV narrow-spectrum antibiotics. The fourth IV and second antibiotic class of
IV’s of “narrow-spectrum antibiotics” was coded as “NS.” NS was defined as antibiotics
that target specific pathogens. Antibiotics selected for this study, including NAMCS
codes (n.d.) were Clindamycin/Cleocin (6920/6905),
Macrobid/Nitrofurantoin/Macrodantin (93090/18130), and Trimethoprim (32438). See
Table 3.
Measurement of NS. NS was measured as “1=Narrow-Spectrum Antibiotics
Prescribed, and, 0=Narrow-Spectrum Antibiotics Not Prescribed.”
IV broad- and narrow-spectrum antibiotics. The final antibiotic class of IV’s of
“broad- and narrow-spectrum antibiotics” was coded as “BSNS.” BSNS was defined as
either having both broad- and narrow-spectrum antibiotics prescribed during one visit, or,
one medication that has a combined chemical combination of a broad-spectrum and a
narrow-spectrum antibiotic. Antibiotics selected for this study, including their relevance
NAMCS codes (n.d.) were Bactrim/Trimethoprim-Sulfamethoxazole
(32423/3430/1017/29843). See Table 3.
Measurement of BSNS. BSNS was measured as “1=Broad- and Narrow-spectrum
Antibiotics Prescribed, and, 0=Broad- and Narrow-spectrum Antibiotics Not Prescribed.”
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Table 3
Summary of Independent Variables and Antibiotic Classes Prescribed
Variable type

Variable

Independent

Initial
Antibiotics
Prescribed

Independent

Continued
Antibiotics
Prescribed

Independent

NarrowSpectrum
Antibiotics

Independent

Combined
Broad &
NarrowSpectrum
Antibiotics

Variable
description
1. A new patient
visit related to
UTI
signs/symptoms
with onset less
than 3 months
And
2. One or More
initial
antibiotics
were
prescribed
1. Recurrent visit
via referral or
previously
seen by
primary
provider
related to UTI
with onset less
than 12
months
And
2. One or more
antibiotics
prescribed are
continued

Coded value

Measure

Measure

INABXRX

“1” = Initial
Antibiotic
Prescribed
Meets
Defined
Criteria

“0” = Initial
Antibiotic
Prescribed
Does Not
Meet Defined
Criteria

CONABXRX

“1” =
Continued
Antibiotics
Prescribed
Meets
Defined
Criteria

“0” =
Continued
Antibiotics
Prescribed
Does Not
Meet Defined
Criteria

Class of
Antibiotics that
targets specific
pathogens in the
treatment of an
infection

NS

1. Prescribed Both
Broad &
NarrowSpectrum
Antibiotics at
the same visit

BSNS

“1” =
NarrowSpectrum
Antibiotic
Prescribed
Meets
Defined
Criteria
“1” = Broad
& NarrowSpectrum
Antibiotics
Prescribed
Meets
Defined
Criteria

“0” =
NarrowSpectrum
Antibiotic
Prescribed
Does Not
Meet Defined
Criteria
“0” = Broad
& NarrowSpectrum
Antibiotics
Prescribed
Does Not
Meet Defined
Criteria
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Antibiotic class relevance. The relevance of these two classes of antibiotics is that
they include most all classes of antibiotics that are currently used in the U.S. to treat
infections (Ventola, 2015), and implicated in the progression of antibiotic-resistant UTIs
(Pallett & Hand, 2010; Bartlett, 2011). This study had included all broad- and narrowspectrum antibiotics available in the study data. Studies indicate that providers have been
prescribing both broad-spectrum and other antibiotic classes simultaneously for the initial
treatment of UTIs (Leekha, Terrell, & Edson, 2011). This method has been questioned as
it is deemed an inappropriate way to practice prescribing antibiotics (Karam, Chastre,
Wilcox, & Vincent, 2016) and has negative consequences documented with
epidemiologically important gram-negative pathogens in UTIs (Nienhouse, 2014).
Gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus
(MRSA), is also of epidemiological importance, however, gram-negative pathogens are
tougher to treat (Soto, 2014). The literature has evidenced that most complaints about
“UTIs” are that the cultures do not grow substantial amounts of bacteria and yet
antibiotics are prescribed without an appropriate indication (2010). A cost-effective
alternative to antibiotics has been documented in the literature as a simple urinalysis test,
or “UA” (Brusch & Bronze, 2015). To demonstrate the impact, Al-Badir & Shaikh
(2013) discussed that asymptomatic bacteriuria accounts for about 8% of health care
visits where more than 25% of antibiotics are prescribed but rarely ever indicated
(Shapiro, 2013). Shapiro et al. (2013) noted that 61% of antibiotics prescribed during
ambulatory care visits broad-spectrum antibiotics and of these, macrolides, quinolones,
and aminopenicillins accounted for between 12 and 25% of all antibiotics prescribed.
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IV Ages. The IV of ages were coded as “AGES.” AGES were defined as those
visits whose ages were between 25-44. See Table 4.
Measurement of AGES. AGES were measured as “1 = 25-29, 2 = 30-34, 3 = 3539, and 4 = 40-44.”
IV Region. The IV of region was codes as “REGION.” REGIONS were defined
as those regions of the United States that were included in the NAMCS surveys.
Measurement of REGION. REGION was measured as “1 = Northeast, 2 =
Midwest, 3 = South, and 4 = West.” See Table 4.

Table 4
Summary of Independent Variables of Region and Ages
Variable type

Variable

Independent

Ages

Independent

Regions

Variable
description
Includes ages
25-44

Coded value

Measure

AGES

1 = 25-29
2 = 30-34
3 = 35-39
4 = 40-44

Includes the
four major
regions that
NAMCS
collected data
from in the
United States:
Northwest,
Midwest,
South, and
West

REGION

1 = Northeast
2 = Midwest
3 = South
4 = West
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Data Analysis Plan
Data Selection
Data selected for analysis were abstracted from NAMCS datasets and summary
tables from the CDC website for the survey (2014). The analysis included my study
period of 2008-2012; years’ 2013-2015 were not utilized due to that the data was not
publicly available when my study was designed (CDC, 2015a). The dependent and
independent variable data abstracted from the national data set included for analysis was
first done with Excel via a comma separated value (CSV) file that was already prepared
for use on the NAMCS website. NAMCS data sets utilized are public, secure, and webbased with Centers for Disease Control & Prevention (CDC) ownership and management
of this data (CDC, 2014). The CSV file was scrubbed and recoded to include only
relevant data elements for this study. SPSS, version 23, was utilized for the cohort
analysis measures of exposures and outcomes. Many of the original code labels in the
CSV file were changed for this study so that they were easily identifiable.
The NAMCS public database did not include patient identifiers, therefore it was
not necessary to replace patient identity with coding. The independent and dependent
variables were either pre-assigned data codes, or I had assigned data codes for analysis.
Variances can be produced according to NCHS (2015) by using a generalized variance
curve which is discussed in the public-use file literature (2015).
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Statistical Testing
Testing for logistic regression was carried out in SPSS to examine whether the
independent variables of initial antibiotics prescribed, continued antibiotics prescribed, or
broad, narrow, and broad- and narrow-spectrum-combined antibiotics predicted the DV,
UTI antibiotic resistance. To assess variability on the dependent variable, the independent
variables as predictors utilized the Nagelkerke R2. Cross tabs were executed to examine
the association between DV and IV’s, along with Fisher’s Exact Test; Fisher’s will be
utilized for analysis due to the small sample. Binary Logistic regression was executed for
initial and continuous antibiotic prescribing, and also the classes of antibiotics included
(broad, narrow, and combined broad- and narrow-spectrum) to illustrate the overall
relationships of the IV’s significance for logistic regression.
To assess individual predictors and the model fit, Hosmer-Lemeshow and Wald
were applied to test the null hypothesis. Classification utilized for the variables and
evidenced with a contingency table were: “Expected” (Exp), for the null, which is also
written as the number of cases predicted (indicated by 0 or 1) divided by “Observed”
(OBS), or the number counted. The odds ratio, or in binary regression known as Exp(B),
was analyzed to determine event occurrence probability predictions. Significance was
analyzed by using .05, and was identified as significant, >1 will; a 95% CI was
additionally included for analysis. The greater the significance of each independent
variable over 1.0, the more likely there will be for a risk with UTI antibiotic resistance.
Omnibus testing was conducted to test the intercept-only with the fitted model using Chisquare; p-values were interpreted.
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Many of the restrictions placed on assumptions with linear regression are not an
issue with logistic regression testing (Woltman, Feldstain, MacKay, & Rocci, 2012). A
good example of this is that there were no assumptions made for equal variances,
normality, or linearity as well as normal distribution was never assumed with an error
term variance. The outcome (DV) was dichotomous and separate. With logistic
regression, a large sample would have been optimal to use to achieve maximum likely
outcomes, however, the sample size was ultimately small and was utilized to conduct
analysis. I chose a public data file with a national sample that was very large and was
hopeful that this would complement my use of discrete variables so that there was enough
data to analyze each variable chosen.
Research Question 1: Are initial antibiotics prescribed for UTIs associated with
UTI antibiotic resistance?
Ho1: There is no statistically significant association between antibiotic resistance
in UTIs and initial antibiotics prescribed.
Ha1: There is a statistically significant association between antibiotic resistance in
UTIs related and initial antibiotics prescribed.
Logistic regression was carried out to test the first hypothesis that there is no
statistically significant relationship between continued antibiotics prescribed and UTI
antibiotic resistance in nonpregnant females, age 25-44, on Medicaid, in U.S. ambulatory
care settings. To test the hypothesis, the statistical significance used was a p-value of
0.05. A p-value of <0.05 indicated rejection of the null hypothesis and failure to reject the
alternative hypothesis. Prevalence rate will additionally be calculated.
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Research Question 2: Are continued antibiotics prescribed for UTIs associated
with UTI antibiotic resistance?
Ho2: There is no statistically significant association between antibiotic resistance
in UTIs and continued antibiotics prescribed.
Ha2: There is a statistically significant association between antibiotic resistance in
UTIs and continued antibiotics prescribed.
Logistic regression was carried out to test the second hypothesis that there is no
statistically significant relationship between continued antibiotics prescribed and UTI
antibiotic resistance in nonpregnant females, age 25-44, on Medicaid, in U.S. ambulatory
care settings. To test the hypothesis, the statistical significance used was a p-value of
0.05. A p-value of <0.05 indicated rejection of the null hypothesis and failure to reject the
alternative hypothesis. Prevalence rate will additionally be calculated.
Research Question 3: Is the class of antibiotic prescribed for UTIs associated with
UTI antibiotic resistance?
Ho3: There is no statistically significant association between UTI antibiotic
resistance and class of antibiotic prescribed.
Ha3: There is a statistically significant association between UTI antibiotic
resistance and class of antibiotic prescribed.
Logistic regression was carried out to test the third hypothesis that there is no
statistically significant difference in antibiotic resistance in UTIs in low-income
nonpregnant females age 25-44 related and initial antibiotics prescribed. The dependent
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variable was UTI antibiotic resistance. To test the hypothesis, the statistical significance
used was a p-value of 0.05. A p-value of <0.05 indicated
rejection of the null hypothesis and failure to reject the alternative hypothesis. Prevalence
rate will additionally be calculated.
Threats to Validity
Data quality procedures for this study looked at those internal and external threats
to validity that could occur and directly impact reliability and validity (Dyck, Culp, &
Cacchione, 2007). Internal validity may likely be threatened from within the sample
selected. The study sample chosen may not be representative of all females on Medicaid
because disease likelihood would be related to racial and ethnic genetic traits; only black,
white, and Hispanic or Latino, and “others” were utilized in the NAMCS study (2011;
2012). Access to a more detailed account of patient characteristics was not available in
the NAMCS public data sets.
To increase the probability of patient characteristics, random selection will be
utilized (Creswell, 2009). External validity threats occur when study results are applied to
other populations (Steckler & McLeroy, 2008). The threat potentially lies with the fact
that the primary study population was not federally-based ambulatory care facilities, and
not inclusive of veterans, military ambulatory care, and outpatient public health clinics,
emergency departments or acute care (emergency) department. Ambulatory care clinics
that are federally funded, would be considered special populations a special and would
not be generalizable. To manage this threat, study results would need to restrict those
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patients who, in addition to receiving health care at non-federal ambulatory care facilities,
including those ambulatory care clinics within a hospital facility, also receive health care
at federal ambulatory care facilities such as the VA, military clinic, or public health
clinic.
Ethical Procedures
This study was performed using a national, public secondary database, available
on the internet via the CDC study website for the National Ambulatory Medical Center
Survey (NAMCS). All patient data had been de-identified by the original surveyors prior
to posting to the internet. The design variables according to the National Center for
Health Statistics (NCHS), are confidential and have never been released to the public.
Variances can be produced according to NCHS (2015) by using a generalized variance
curve which is discussed in the public-use file literature (2015).
According to NCHS (2015), the NAMCS is governed by Title 42, United States
Code, and Section 242K, which permits data collection for health research. Title 42,
United States Code, Section 242m (d) provides data confidentiality. The statistical
purpose is the only reason that the survey data may be collected. “No information that
could identify a person or establishment can be released to anyone, including the
President, Congress, or any court, without the consent of the provider” (2015). The data
must be protected according to many laws such as but not limited to the Privacy Act, and
the Public Health Service Act; Census Bureau staff must sign a declaration of facts
(2015). Healthcare-providers and patients can be confident that The NCHS and Census
Bureau are protecting everyone’s privacy, as evidenced by a perfect record of privacy
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protection (2015). The Walden University Internal Review Board (IRB) governs the
handling of all study data; this study followed these procedures for collection and
handling of the data.
Summary
For this study, an observational cohort, the retrospective approach was utilized to
characterize the relationship between the dependent variable of UTI antibiotic-resistance
incidence and the related independent variables of initial, continued, broad-spectrum,
narrow-spectrum, and broad/narrow-spectrum antibiotics prescribed, to nonpregnant
females, ages 25-44, on Medicaid who were seeking care for UTI symptoms in an
ambulatory setting. The study purpose was to examine nonpregnant American female
patients who were exposed to poverty and at risk for antibiotic resistance when seeking
care for UTIs in ambulatory care settings. This was accomplished using secondary data
from a cohort of U.S. ambulatory care facilities from large national surveys that are
conducted annually in the United States by NAMCS, a branch of the Centers for Disease
Control and Prevention (CDC) (NAMCS, 2008; 2009; 2010; 2011; 2012).
Statistically significant relationship testing between the independent variables to
understand why female low-income populations in ambulatory care are at risk for UTI
antibiotic resistance was the basis for the data collection and analysis. Statistical analysis
via binary logistic regression for the three hypotheses was completed. The next chapter,
chapter 4, will detail the results of the analysis activities.
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Chapter 4: Results
The purpose of this study was to examine nonpregnant U.S. female patients who
were exposed to poverty and at risk for UTI antibiotic resistance. The cohort was
secondary data selected from a publicly-available data repository in the United States.
This study investigated three key research questions. Research Question 1 (Are initial
antibiotics prescribed for UTIs associated with UTI antibiotic resistance?) was designed
to investigate whether the very first round of antibiotics prescribed for uncomplicated
UTIs in nonpregnant females who had sought care in ambulatory settings might be
contributing to antibiotic resistance.
Very few studies in the United States about prescribing patterns of ambulatory
care providers have been completed (Costelloe, Metcalfe, Lovering, Mant, & Hay, 2010;
Wong et al., 2017). The first round of antibiotics is often prescribed empirically without a
culture to prove what antibiotic is necessary to cure a UTI infection (Gibson & Toscano,
2012). The duration and timing of antibiotic therapy has also been in question
(Grigoryan, Zoorob, Wang, & Trautner, 2015). Research Question 2 (Are continued
antibiotics prescribed for UTIs associated with UTI antibiotic resistance?) proposed that,
when patients returned for care because of UTI symptoms that were not going away, the
same or different antibiotics prescribed were contributing factors for antibiotic resistance.
Research Question 3 (Is the class of antibiotics prescribed for UTIs associated with UTI
antibiotics resistance?) was planned to capture the class of antibiotic that may have been
contributing to initial or continued antibiotic prescribing and that may have been related
to antibiotic resistance. It has been demonstrated that antibiotic guidelines and the actual
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class of antibiotics used for UTIs in ambulatory care settings are disparate (Grigoryan et
al., 2015).
Data Collection
Data sets, or, more specifically, CSV data file sets for the years 2008-2012) were
downloaded from the National Bureau of Economic Research’s (NBER) website. This
website is a national storage site for this type of data that contains research files in
various formats as well as codebooks (National Bureau of Economic Research [NBER],
n.d.). Data sets available on the NAMCS website did not include CSV-type files.
However, SPSS-ready files were available. CSV-type data were selected for initial data
abstraction and the scrub process. SPSS data files were also downloaded directly from the
NAMCS webpages and compared to the NBER files for quality assurance.
After the CSV files for Microsoft Excel from NBER were validated for
completeness of data, each year’s worth of data was scrubbed to meet the ambulatory
patient population criteria for my sample frame. These criteria included being female,
between the ages of 25-44, and being a recipient of Medicaid. Criteria also included
diagnoses variables. The sample frame also included nonpregnant women. Only the 2012
data set included a new variable developed by NAMCS labeled “PREGNANT,” which
identified a pregnant patient. Therefore, for years 2008-2011, NAMCS codes indicating a
current pregnancy state, such as reason for visit (RSV), medications (MED), and ICD9
codes for diagnosis (DIAG), were reviewed and scrubbed. Those cases that were
identified as meeting criteria per codes for a positive current pregnancy status were
deleted from the cohort sample. The data were further sorted to delete the multiple
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extraneous variables that were present and would not be utilized by this study; this made
the data more manageable. A separate Excel file was created in CSV format, and each
year’s worth of scrubbed data was cut and pasted into this file to form one complete file
for years’ 2008-2012.
Case-Finding
Initially, to ensure research standards with data were met, I reviewed all NAMCS
and HAI definitions, then performed any necessary variable remodeling. NAMCS survey
years 2008-2012 were reviewed. Regions used in the parent study (Northeast [1],
Midwest [2], South [3], and West [4]), were noted as well as Ages 25-44. The first step
involved using NAMCS’ study’s definitions and inserting dummy variables that would
better serve the analysis. All variables were identified by the dependent variable (DV)
definition were located: (diagnosis) “DIAG1, DIAG2, DIAG3,” (reason for visit) “RFV1,
RFV2, RFV3,” (medication) “MED1-MED8,” and (new medication/continued
medication) “NUMED, CONTMED.” The independent variables of NUMED and
CONTMED represented both initial and continuous prescribing as well as prescribing in
12 months or less.
A new variable column labeled “UAR,” depicting dichotomous DV UTI
resistance, was then inserted into the CSV data file used for this study. To properly have
a defined DV (UAR), it was critical that all diagnoses, reasons for visit, and medications
were reviewed with each year’s code book. Each case that met criteria was entered into
the variable UAR as “1,” and, each case that did not meet criteria was entered in as “0.”
All codes in each of these categories that were related to an acute urinary tract infection

68
(upper or lower) were reviewed and logged for UTI exposure relevance: the sample
(n=45) met criteria for UTI exposure out of the sample frame (total nonpregnant female,
ages 25-44, on Medicaid, and with a positive diagnosis/symptom of UTI (N=51).
Subsequently, the Excel file with all case variables were exported and uploaded into
SPSS for analysis.
SPSS Variable View
Once the data were uploaded to SPSS, in “Variable View” (SPSS), each variable
header was reconfigured to represent the variable type (numerical) to conduct analysis
appropriately. Changes made in variable view: labels were entered; values reflecting the
outcome were input; missing data was reviewed and corrected if necessary; measure
(ordinal/nominal/scale) was indicated.
Sample Size
As discussed in Chapter 3, simple random sampling calculation conducted
electronically was executed by utilizing the total sample frame (N=51), a confidence level
of 95%, a confidence interval of 0.05 (upper 0.55, lower 0.45), standard error of 0.03
relative standard error of 5.10, and power of 80%. The results had indicated that a
minimum sample size of 45 was necessary to perform this study. SPSS was utilized to
perform random sampling; N=51 was input as criteria for the random sample. Probability
sampling was utilized because it has been shown to provide better assurance that the
sample is representative of the population (Omair, 2014).
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Results
The sample frame (N=51) was downloaded into SPSS version 23 from Microsoft
Excel and a final sample of n=45 was produced. Descriptive statistics was utilized to
summarize the demographic sample and antibiotics prescribed.
Assumption Errors and Inquiry
Before the investigation of this study’s research questions could begin, frequency
distribution, errors, and assumptions were investigated in SPSS. To describe the
interactions between two categorical IVs, crosstabs was utilized to create contingency
tables. Frequency tables were also created for single categorical variables such as
demographics (See Table 5), timing of antibiotics prescribed (initial or continued), and
each class of antibiotics (broad-spectrum, narrow-spectrum, and combined broad- and
narrow-spectrum (see Table 6).
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Table 5
Frequencies and Percentages for Sampled Population Age, Region, Visit Year, Visit
Month, and Visit Day of the Week with Symptomatic UTI
N

Percent
(%)

Age frequency and percentage with UTI symptoms
25-29
30-34
35-39
40-44

15
12
9
9

33.2
26.7
20.0
20.0

Region frequency and percentage with UTI symptoms
Northeast
Midwest
South
West

10
7
12
11

22.2
15.6
26.7
24.4

2
3
5
6
2
3
2
2
3
5
8
4

4.4
6.7
11.1
13.3
4.4
6.7
4.4
4.4
6.7
11.1
17.8
8.9

12
11
9
7
5

26.7
24.4
20.0
15.6
11.1

Year visit frequency and percentage with UTI symptoms
January
February
March
April
May
June
July
August
September
October
November
December
Day of the week visit frequency and percentage with UTI symptoms
Monday
Tuesday
Wednesday
Thursday
Friday
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Table 6
Frequency Distribution of Timing and Antibiotic Class Prescribing for UTI Symptoms
Frequency

Percent

BS Antibiotics Not Prescribed

21

46.7

BS Antibiotics Prescribed

24

53.3

Total

45

100.0

NS Antibiotics Not Prescribed

29

64.4

NS Antibiotics Prescribed

16

35.6

Total

45

100.0

BSNS Antibiotics Not Prescribed

38

84.4

BSNS Antibiotics Prescribed

7

15.6

Total

45

100.0

Summary Population Frequency Distribution
Of the 45 patients in the sample between the ages of 25-44, the average age of
nonpregnant females on Medicaid was 33. The age in this sample who visited
ambulatory care the most were 25-29-year-olds (33.2%). The region that reported the
most visits by nonpregnant ambulatory care patients were from the Southern region of
the U.S (26.7%). Data concluded that nonpregnant females, ages 25-44, and on
Medicaid, were also more likely to visit ambulatory care on a Monday (26.7%) during
the month of November (17.8%). During the years utilized for this study, 2008-2012,
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2009 received the most visits (40%) by the sample population in ambulatory care
settings.
Summary Antibiotic Timing and Class Frequency Distribution
Next, frequency distributions of prescribing antibiotics were run on initial
antibiotics prescribed (INABXRX) in 3 months or less for a symptomatic UTI (Figure
1), and, continuous antibiotics prescribed (CONTABXRX) (Figures 2) in 12 months or
less for a symptomatic UTI. Additionally, frequency tables were provided for those
classes of antibiotics included in this study that were prescribed for a symptomatic UTI:
broad-spectrum antibiotics prescribed (BS), narrow-spectrum antibiotics prescribed
(NS), and combined broad & narrow-spectrum antibiotics prescribed (BSNS) (see Table
3 and Figures 3, 4, 5). There appears to be a higher frequency (36%) of utilization with
initial antibiotics prescribed than continued prescribing.
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Figure 1. Bar chart of Frequency of Initial Antibiotics Prescribed in 3 Months or Less.
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Figure 2. Bar Chart of Frequency of Continued Antibiotics Prescribed in 12 Months or
Less
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Figure 3. Bar Chart of Frequency of Broad-Spectrum Antibiotics Prescribed
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Figure 4. Bar Chart of Frequency of Narrow-Spectrum Antibiotics Prescribed
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Figure 5. Bar Chart of Frequency of Combined Broad- and Narrow-Spectrum Antibiotics
Prescribed

Summary of Antibiotic Prescribing Frequency Distribution
Outcome evidence with antibiotic prescribing after frequency distributions were
executed indicated that of the sample (n=45), nonpregnant females, ages 25-44, and on
Medicaid(n=42), were likely to be prescribed initial antibiotics within 3 months 91% of
the time. Those patients who returned to ambulatory care with recurrent symptoms
(n=12), were only likely to have antibiotics continued 55.6% of the time. Patients (n=24)
were more likely (53%) to be prescribed broad-spectrum antibiotics when seeking care in
ambulatory clinics for UTIs compared to narrow-spectrum antibiotics, prescribed 18%
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less frequently than broad-spectrum, and combined broad- and narrow-spectrum
antibiotics, prescribed 38% less frequently than broad-spectrum antibiotics. Narrowspectrum antibiotics (n=16) were only prescribed 36% of the time, and combined broadand narrow-spectrum antibiotics (n=7) were only prescribed 16% of the time.
Research Question 1
Research Question 1: Are initial antibiotics prescribed for UTIs associated with
UTI antibiotic resistance?
Ho1: There is no statistically significant association between antibiotic resistance
in UTIs and initial antibiotics prescribed.
Ha1: There is a statistically significant association between antibiotic resistance in
UTIs and initial antibiotics prescribed.
To analyze research question 1, testing for an association, followed by binary
regression and a review of predictor characteristics was executed.
Association.
To test for association between initial antibiotics prescribed (IV), and UTI
antibiotic resistance (DV) crosstabulation was executed and analyzed. A contingency
table was produced (see Table 7) to display variable counts and percentages. Due to the
small sample size and violation of assumptions for Chi-Square testing, Fisher’s Exact test
was reported. The proportion of those patients who were prescribed initial antibiotics in 3
months or less that developed UTI antibiotic resistance (UAR) was 51.2%, or, 21 out of
41 cases.
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Table 7
Initial Antibiotics Prescribed in 3 Months or Less and UTI Antibiotic Resistance
UTI
Resistance
Criteria Not
Met
% Initial
Antibiotics
Not
Prescribed in
3 Months or
Less
% Initial
Antibiotics
Prescribed in
3 Months or
Less

UTI
Resistance
Criteria Met

Total

25%

75%

100%

48.8%

51.2%

100%

Table 7 Contingency Table
It was noted that the results of Fisher’s Exact test (see Table 8) indicated that
there was no statistically significant relationship observed between the exposure to initial
antibiotics prescribed in 3 months or less and UTI antibiotic resistance in nonpregnant
female patients, ages 25-44, on Medicaid, who presented to an ambulatory care clinic
with UTI symptoms; the p-value was >.05 (p=.611) therefore I failed to reject the null
hypothesis (see Table 8).
Table 8
Summary of Fisher’s Exact Test and Initial Antibiotics Prescribed

N
Fisher's Exact Test

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)
.611

45

.357
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Binary logistic regression. Binary logistic regression was executed to analyze
the risk of antibiotic resistance in UTIs in those patients who were prescribed antibiotics
initially for UTI symptoms while controlling for AGES and REGION. The results
indicated that initial prescribing of antibiotics was not a statistically significant predictor
of UTI antibiotic resistance within 3 months or less after the onset of UTI symptoms
(p>.05). There was a large improvement with the inclusion of predictor variables and the
model fit (X2=5.502(8), p=.703, Nagelkerke R2= .153). The final model, however
indicated that AGES and REGION had very little effect on initial antibiotics prescribed
(p= >.05). No further predictions were made thus I failed to reject the null hypothesis.
The results of binary regression with initial antibiotics prescribed predicting UTI
antibiotic resistance in 3 months or less can be reviewed in Table 9.
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Table 9
Summary of Binary Logistic Regression and Initial Antibiotics

B

Sig.

β

1.34

.301

3.82

AGES (1)

-1.086

.258

.338

AGES (2)

.248

.813

1.28

AGES (3)

-.216

.839

.806

REGION (1)

.077

.950

1.080

REGION (2)

.570

.558

1.77

REGION (3)

-.229

.831

.795

REGION (4)

.783

.380

2.19

Variables

INABAXRX

Notes. R2 = .153 (p>.05)
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To examine the first binary logistic regression model, the Hosmer and Lemeshow
test was processed along with a classification table to check for the model fit. Hosmer
and Lemeshow indicated that there was a significant improvement between the observed
data in block 0 and the final regression model, therefore this model appeared to be a good
fit (>.05) for the data at an acceptable level (X2=2.594(7), p=.920). The results of the
model summary concluded that between 11% and 15% of the variation in UTI antibiotic
resistance was explained by the final model. The correct classification rate increased by
13% (51.1 to 64.4.).
A review of the variables in the equation were analyzed. The variable, initial
antibiotics prescribed (INABXRX), did not appear to contribute to the model; initial
antibiotics prescribed are not statistically significant (>.05, p= .301). The positive
coefficient B indicated that the target group had more cases coded as “1” (initial
antibiotics prescribed) than “0” (initial antibiotics not prescribed). Negative coefficients
(B) for AGES (1) (25-29-year-olds), AGES (3) (35-39-year-olds), and REGION (3)
(Southern United States) indicated that these groups had less cases coded as “1.” Age
(AGES) and Region (REGION) overall were not significant. The coefficient (B) for
initial antibiotics prescribed revealed that the odds of UTI antibiotic resistance was 1.340
more likely for those prescribed initial antibiotics. The Sig. (.301) concluded that the chi
square test for UTI antibiotic resistance versus initial antibiotics prescribed were not
statistically significant, therefore I failed to reject the null hypothesis; data remains
inconclusive because there is insufficient evidence at the alpha level of significance to
reject the claim that initial antibiotics prescribed are related to UTI antibiotic resistance.
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The odds for those patients who were prescribed initial antibiotics for symptomatic UTIs
were 3.821 (95%CI .302 to 48.364) times more likely to have UTI antibiotic resistance in
an ambulatory care setting when prescribed antibiotics initially for a UTI. Since the CI
(confidence interval) spans 1.0, the increased odds (3.821) of UTI antibiotic resistance
among nonpregnant females, ages 25-44, and on Medicaid, who were prescribed
antibiotics initially for UTIs at baseline, does not reach statistical significance.
Predictor characteristics. Predictor characteristics based on descriptive
measures of prevalence and incidence, were calculated for initial antibiotics and UTI
antibiotic resistance (see Table 10). The prevalence of UTI antibiotic resistance in the
total number of sample cases with UTI antibiotic resistance (n=45) was 9% when
prescribed initial antibiotics. The incidence rate (new cases of antibiotic resistant UTIs)
for those at risk in 3 months or less was 7%.
Table 10
Predictor Characteristics of Initial Antibiotics Prescribed
Initial
Antibiotics Prescribed

Prevalence

Incidence

9%

7%

Research Question 2
Research Question 2: Are continued antibiotics prescribed for UTIs associated
with UTI antibiotic resistance?
Ho2: There is no statistically significant association between antibiotic resistance
in UTIs and continued antibiotics prescribed.
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Ha2: There is a statistically significant association between antibiotic resistance in
UTIs and continued antibiotics prescribed.
To analyze research question 2, testing for an association, followed by binary
regression and a review of predictor characteristics was executed.
Association.
To test for association between continued antibiotics prescribed (IV), and UTI
antibiotic resistance (DV) crosstabulation was executed and analyzed. A contingency
table was produced (see Table 11) to display variable counts and percentages. Due to the
small sample size and violation of assumptions for Chi-Square testing, Fisher’s Exact test
was reported. The proportion of those patients who were prescribed continued antibiotics
for recurrent UTIs in 12 months or less who developed UAR was 84.6%, or, 22 out of 26
cases (see table 11).
Table 11
Continued Antibiotics Prescribed in 12 Months or Less and UTI Antibiotic Resistance
UTI
Resistance
Criteria Not
Met
% Continued
Antibiotics
Not
Prescribed in
12 Months or
Less
% Continued
Antibiotics
Prescribed in
12 Months or
Less

UTI
Resistance
Criteria Met

Total

94.7%

5.3%

100%

15.4%

84.6%

100%

Table 11 Contingency Table
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Fisher’s Exact test (see Table 12) evidenced a statistically significant relationship
observed between the exposure to continued antibiotics prescribed in 12 months or less
and UTI antibiotic resistance in nonpregnant female patients, ages 25-44, on Medicaid,
who presented to an ambulatory care clinic with UTI symptoms; the p-value was <.05
(p=.000) therefore the null hypothesis was rejected (see Table 12).

Table 12
Summary of Fisher’s Exact Test and Continued Antibiotics Prescribed
n
Fisher's Exact Test

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

.000

.000

45

Binary logistic regression. Binary logistic regression was executed to analyze
the risk of antibiotic resistance in UTIs in those patients whose antibiotics were continued
for UTI symptoms while controlling for AGES and REGION. The results indicated that
continued prescribing of antibiotics was not a statistically significant predictor of UTI
antibiotic resistance within 12 months or less after the onset of UTI symptoms (p>.05).
There was an improvement for fit with the inclusion of the variables (X2=42.098, p=.000,
Nagelkerke R2= .810). The final model, however, indicated that the inclusions of AGES
and REGION had very little associated with continued antibiotics prescribed. No further
predictions were made, thus I failed to reject the null hypothesis. The results of binary
regression with continued antibiotics prescribed predicting UTI antibiotic resistance in 12
months or less can be reviewed in Table 13.
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Table 13
Summary of Binary Logistic Regression and Continued Antibiotics
B

Sig.

β

CONABAXRX

-55.26

.997

.000

AGES (1)

-18.73

.998

.000

AGES (2)

-17.39

.998

.000

AGES (3)

34.67

.997

1.138E+15

REGION (1)

-1.03

.579

.358

REGION (2)

-.231

.899

.794

REGION (3)

17.26

.998

31465879.291

REGION (4)

.-.427

.780

.653

Variables

Notes. R2 = .810 (p>.05)
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To examine the second binary logistic regression model, the Hosmer and
Lemeshow test was processed along with a classification table to check for the model fit.
Hosmer and Lemeshow indicated that there was a significant improvement between the
observed data in block 0 and the final regression model, therefore this model appeared to
be a good fit (>.05) for the data at an acceptable level (X2=1.201(6), p=.977). The results
of the model summary concluded that between 60% and 80% of the variation in UTI
antibiotic resistance was explained by the final model. The correct classification rate
increased by 38% (51.1 to 88.9.).
A review of the variables in the equation were analyzed. The variable, continued
antibiotics prescribed (CONABXRX), did not appear to contribute to the model;
continued antibiotics prescribed were not statistically significant (>.05, p= .997). The
negative coefficient B indicated that the target group had less cases coded as “1”
(continued antibiotics prescribed) than “0” (continued antibiotics not prescribed), and
was not significant after controlling for the other variables. Age (AGES) and Region
(REGION) did not contribute to the model and were not significant. The coefficient (B)
revealed that the odds of UTI antibiotic resistance was .000 more likely for those
prescribed continued antibiotics. The Sig. (.997) concluded that continued antibiotics
prescribed were not statistically significant, therefore I failed to reject the null hypothesis;
data remains inconclusive because there is insufficient evidence at the alpha level of
significance to reject the claim that the continuation of antibiotics prescribed are related
to UTI antibiotic resistance The odds for those patients who were prescribed continued
antibiotics for symptomatic UTIs were .000 (95%CI .000 to .000) neither more or less
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likely to have UTI antibiotic resistance in an ambulatory care setting when prescribed
antibiotics initially for a UTI. Since the CI (confidence interval) was 0, the increased
odds (.000) of UTI antibiotic resistance among nonpregnant females, ages 25-44, and on
Medicaid, who were continued on antibiotics prescribed for UTIs at baseline, did not
explain any statistical significance.
Predictor characteristics of continued antibiotics. Predictor characteristics
based on descriptive measures of incidence and prevalence were calculated for continued
antibiotics and UTI antibiotic resistance (see Table 14). The prevalence of UTI antibiotic
resistance in the total number of sample cases with UTI antibiotic resistance (n=45) was
51% when antibiotics prescribed were continued for recurrent UTIs. The incidence rate
(new cases of antibiotic resistant UTIs) for those at risk in 12 months or less was 49%

Table 14
Predictor Characteristics of Continued Antibiotics Prescribed
Continued
Antibiotics Prescribed

Prevalence

Incidence

51%

49%

Research Question 3
Research Question 3: Is the class of antibiotic prescribed for UTIs associated with
UTI antibiotic resistance?
Ho3: There is no statistically significant association between UTI antibiotic
resistance and class of antibiotic prescribed.
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Ha3: There is a statistically significant association between UTI antibiotic
resistance and class of antibiotic prescribed.
Association.
To test for association between the various classes of antibiotics prescribed (IVs),
and UTI antibiotic resistance (DV) crosstabulation was executed and analyzed, and
predictor characteristics were discussed. A contingency table was produced (see Table
15) to display variable counts and percentages. Due to the small sample size and violation
of assumptions for Chi-Square testing, Fisher’s Exact test was reported. The proportion
of those patients who were prescribed broad-spectrum antibiotics for symptomatic UTIs
in 12 months or less and developed UAR was 79.2% (19 out of 24 patients); narrowspectrum antibiotic exposure associated with UTI antibiotic resistance was 31.3% (5 out
of 16 patients); and an exposure to a combination of broad- and narrow-spectrum
antibiotics was 57.1% (4 out of 7 patients) (see table 15).
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Table 15
Classes of Antibiotics Prescribed in 12 Months or Less and UTI Antibiotic Resistance

Class of
Antibiotics

% BroadSpectrum
Antibiotics
Not
Prescribed
% Broadspectrum
Antibiotics
Prescribed
% NarrowSpectrum
Antibiotics
Not
Prescribed
% NarrowSpectrum
Antibiotics
Prescribed
% Combined
Broad &
NarrowSpectrum
Antibiotics
Not
Prescribed
% Combined
Broad &
NarrowSpectrum
Antibiotics
Prescribed

UTI
Resistance
Criteria Not
Met

UTI
Resistance
Criteria Met

Total

81.0%

19.0%

100%

20.8%

79.2%

100%

37.9%

62.1%

100%

68.8%

31.3%

100%

50%

50%

100%

42.9%

57.1%

100%

Table 15 Contingency Table
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The results of Fisher’s Exact test (see Table 16) did not indicate a statistically
significant relationship (<.05) observed between an exposure with the broad-spectrum
(.000) class of antibiotics prescribed in 12 months or less and UTI antibiotic resistance in
nonpregnant female patients, ages 25-44, on Medicaid, who presented to an ambulatory
care clinic with UTI symptoms. Thus, the null hypothesis was rejected for broadspectrum antibiotic prescribing. There were, however, statistically significant
relationships observed in both narrow-spectrum and combined broad- and narrowspectrum antibiotics prescribed (p>.05): .065 (NS); 1.00 (BSNS). Thus, I failed to reject
the null hypotheses for narrow-spectrum and combined broad- and narrow-spectrum
antibiotics (see Table 16).

Table 16
Summary of Fisher’s Exact Test and Classes of Antibiotics Prescribed
n

Exact Sig. (2-Sided)

Exact Sig. (1-Sided)

Fisher’s Exact
Test
BSABX

45

.000

.000

NSABX

45

.065

.047

BSNSABX

45

1.00

.526

Binary logistic regression. Binary logistic regression was executed to analyze
the risk of antibiotic resistance in UTIs in those patients exposed to three distinct classes
of antibiotics (broad-spectrum, narrow-spectrum, and combined broad- and narrowspectrum), while controlling for ages (AGES, (1)25-29, (2)30-34, (3)35-39, (4)40-44),
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region (REGIONS, (1) Northeast, (2) Midwest, (3) South, and (4) West), initial
antibiotics prescribed (INABXRX), and continued antibiotics prescribed (CONABXRX).
Coding of the variables BS, NS, and BSNS was indicated by “0=Broad/ Narrow/
Combined Broad- and narrow-spectrum antibiotics not prescribed,” and “1=Broad/
Narrow/ Combined Broad- and narrow-spectrum antibiotics prescribed.
Broad-spectrum antibiotics and binary logistic regression. The results of Broadspectrum antibiotics as a predictor of UTI antibiotic resistance indicated that this was not
a statistically significant predictor after the onset of UTI symptoms (p>.05). AGES,
REGION, INITIAL, and CONTINUED were controlled for (R2.923 (10), p= 52.997).
Thus, I failed to reject the null hypothesis. The results of binary regression with broadspectrum antibiotics prescribed predicting UTI antibiotic resistance in 12 months or less
can be reviewed in Table 17.

93
Table 17
Summary of Binary Logistic Regression and Broad-Spectrum Antibiotics
B

Sig.

β

BS

-70.11

.995

.000

AGES (1)

-71.36

.997

.000

AGES (2)

-51.49

.999

.000

AGES (3)

52.40

.998

5.694E+22

REGION (1)

-18.28

.996

.000

REGION (2)

14.15

1.00

1390232.41

REGION (3)

15.43

1.00

5024326.69

REGION (4)

17.59

.997

.000

INABXRX

-35.15

.995

.000

CONABXRX

-71.93

.995

.000

Variables

Notes. R2 = .923 (p>.05)
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To examine the third binary logistic regression model, the Hosmer and Lemeshow
test was processed along with a classification table to check for the model fit. Hosmer
and Lemeshow indicated that there was neither significant or insignificant improvement
between the observed data in block 0 and the final regression model, therefore this model
did not appear to be of a good fit (<.05) without an acceptable level (X2=.000(5),
p=1.000). The results of the model summary concluded that between 69% (Cox & Snell
R2)) and 92% (Nagelkerke R2) of the variation in UTI antibiotic resistance could be
explained by the final model. The correct classification rate had increased by 42% (51.1
to 93.3.).
A review of the variables in the equation were analyzed. The variable, broadspectrum antibiotics prescribed (BS), did not appear to contribute to the model; broadspectrum antibiotics prescribed was not statistically significant (p>.05, p= .995). The
negative coefficient B (-70.105) indicated that the target group had less cases coded as
“1” (broad-spectrum antibiotics prescribed) than “0” (broad-spectrum antibiotics not
prescribed), and was not significant after controlling for the other variables. Age (AGES),
Region (REGION), initial antibiotics prescribed (INABXRX), and continued antibiotics
prescribed (CONABXRX) did not contribute to the model and were not significant
(p>.05). The coefficient (B) revealed that the odds of UTI antibiotic resistance was .000
more likely for those prescribed broad-spectrum antibiotics. The Sig. (p>.05, .995)
concluded that broad-spectrum antibiotics prescribed were not statistically significant,
therefore I failed to reject the null hypothesis and data remains inconclusive because
there is insufficient evidence at the alpha level of significance to reject the claim that
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broad-spectrum antibiotics prescribed are related to UTI antibiotic resistance. The odds
for those patients who were prescribed broad-spectrum antibiotics for symptomatic UTIs
were .000 (95%CI .000 to .000) neither more nor less likely to have UTI antibiotic
resistance in an ambulatory care setting when prescribed antibiotics initially for a UTI.
Since the CI (confidence interval) was 0, the increased odds (.000) of UTI antibiotic
resistance among nonpregnant females, ages 25-44, and on Medicaid, who were
prescribed broad-spectrum antibiotics for UTIs at baseline, did not explain any statistical
significance either way.
Predictor characteristics and broad-spectrum antibiotics Predictor
characteristics based on descriptive measures of incidence and prevalence were
calculated for broad-spectrum antibiotics and UTI antibiotic resistance (see Table 18).
The prevalence of UTI antibiotic resistance in the total number of sample cases with UTI
antibiotic resistance (n=45) was 60% when prescribed broad-spectrum antibiotics. The
incidence rate (new cases of antibiotic resistant UTIs) for those at risk in 12 months or
less was 47%.

Table 18
Predictor Characteristics of Broad-Spectrum Antibiotics Prescribed
BroadSpectrum
Antibiotics Prescribed

Prevalence

Incidence

60%

47%
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Narrow-spectrum antibiotics and binary logistic regression. The results of
narrow-spectrum antibiotics as a predictor of UTI antibiotic resistance indicated that this
was not a statistically significant predictor (R2.841(10), p= 44.837). AGES, REGION,
INABXRX, and CONABXRX were controlled for. Thus, I failed to reject the null
hypothesis (p>.05). The results of binary regression with narrow-spectrum antibiotics
prescribed predicting UTI antibiotic resistance in 12 months or less can be reviewed in
Table 19.
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Table 19
Summary of Binary Logistic Regression and Narrow-Spectrum Antibiotics
B

Sig.

β

NS

-19.73

.998

.000

AGES (1)

-17.55

.998

.000

AGES (2)

-15.93

.998

.000

AGES (3)

36.47

.997

6.875E+15

REGION (1)

-.242

.924

.785

REGION (2)

.382

.845

1.47

REGION (3)

18.06

.998

69985861.09

REGION (4)

.574

.805

1.78

INABXRX

-1.244

.537

.288

CONABXRX

-73.98

.996

.000

Variables

Notes. R2 = .841 (p>.05)
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To examine the fourth binary logistic regression model, the Hosmer and
Lemeshow test was processed along with a classification table to check for the model fit.
Hosmer and Lemeshow indicated that there was neither significant or insignificant
improvement between the observed data in block 0 and the final regression model,
therefore this model did not appear to be of a good fit (<.05) without an acceptable level
(X2=.217(6), p=1.000). The results of the model summary concluded that between 63%
(Cox & Snell R2)) and 84% (Nagelkerke R2) of the variation in UTI antibiotic resistance
could be explained by the final model. The correct classification rate had increased by
49% (51.1 to 91.1).
A review of the variables in the equation were analyzed. The variable, narrowspectrum antibiotics prescribed (NS), did not appear to contribute to the model; narrowspectrum antibiotics prescribed was not statistically significant (p>.05, p= .998). The
negative coefficient B (-19.726) indicated that the target group had less cases coded as
“1” (narrow-spectrum antibiotics prescribed) than “0” (narrow-spectrum antibiotics not
prescribed), and was not significant after controlling for the other variables. Age (AGES),
Region (REGION), initial antibiotics prescribed (INABXRX), and continued antibiotics
prescribed (CONABXRX) did not contribute to the model and were not significant
(p>.05). The coefficient (B) revealed that the odds of UTI antibiotic resistance was .000
more likely for those prescribed narrow-spectrum antibiotics. The Sig. (p>.05, .998)
concluded that narrow-spectrum antibiotics prescribed were not statistically significant,
therefore I failed to reject the null hypothesis; the data remains inconclusive because
there is insufficient evidence at the alpha level of significance to reject the claim that
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narrow-spectrum antibiotics prescribed are related to UTI antibiotic resistance. The odds
for those patients who were prescribed narrow-spectrum antibiotics for symptomatic
UTIs were .000 (95%CI .000 to .000) neither more nor less likely to have UTI antibiotic
resistance in an ambulatory care setting when prescribed antibiotics initially for a UTI.
Since the CI (confidence interval) was 0, the increased odds (.000) of UTI antibiotic
resistance among nonpregnant females, ages 25-44, and on Medicaid, who were
prescribed narrow-spectrum antibiotics for UTIs at baseline, did not explain any
statistical significance either way.
Predictor characteristics and narrow-spectrum antibiotics Predictor
characteristics based on descriptive measures of incidence and prevalence were
calculated for narrow-spectrum antibiotics and UTI antibiotic resistance (see Table 17).
The prevalence of UTI antibiotic resistance in the total number of sample cases with UTI
antibiotic resistance (n=45) was 49% when prescribed narrow-spectrum antibiotics. The
incidence rate (new cases of antibiotic resistant UTIs) for those at risk in 12 months or
less was 31%.

Table 20
Predictor Characteristics of Narrow-Spectrum Antibiotics Prescribed
NarrowSpectrum
Antibiotics Prescribed

Prevalence

Incidence

49%

31%
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Combined broad- and narrow-spectrum antibiotics and binary logistic
regression. Combined broad- and narrow-spectrum antibiotics were not statistically
significant as a predictor of UTI antibiotic resistance within 12 months or less after the
onset of UTI symptoms (R2.873(10), p= 47.818). Thus, I failed to reject the null
hypothesis. The results of binary regression with combined broad- and narrow-spectrum
antibiotics prescribed predicting UTI antibiotic resistance in 12 months or less (see Table
21).
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Table 21
Summary of Binary Logistic Regression and Combined Broad- and Narrow-Spectrum
Antibiotics
B

Sig.

β

BSNS

51.61

.995

2.592E+22

AGES (1)

-43.23

1.00

.000

AGES (2)

-43.23

1.00

.000

AGES (3)

61.17

.999

3.695E+26

REGION (1)

-18.57

.996

.000

REGION (2)

34.14

.996

6.685E+26

REGION (3)

37.71

.999

2.392E+16

REGION (4)

-17.47

.996

.000

INABXRX

-35.40

.995

.000

CONABXRX

-122.97

.994

.000

Variables

Notes. R2 = .873 (p>.05)
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To examine the fifth binary logistic regression model, the Hosmer and Lemeshow
test was processed along with a classification table to check for the model fit. Hosmer
and Lemeshow indicated that there was neither significant or insignificant improvement
between the observed data in block 0 and the final regression model, therefore this model
did not appear to be of a good fit (p<.05) without an acceptable level (X2=.000(6),
p=1.000). The results of the model summary concluded that between 65%(Cox & Snell
R2)) and 87% (Nagelkerke R2) of the variation in UTI antibiotic resistance could be
explained by the final model. The correct classification rate had increased by 40% (51.1
to 91.1.).
A review of the variables in the equation were analyzed. The variable, combined
broad and narrow antibiotics prescribed (BSNS), did not appear to contribute to the
model; combined broad- and narrow-spectrum antibiotics prescribed was not statistically
significant (p>.05, p= .995). The positive coefficient B (51.609) indicated that the target
group had more cases coded as “1” (combined broad- and narrow-spectrum antibiotics
prescribed) than “0” (combined broad- and narrow-spectrum antibiotics not prescribed),
and was not significant after controlling for the other variables. Age (AGES), Region
(REGION), initial antibiotics prescribed (INABXRX), and continued antibiotics
prescribed (CONABXRX) did not contribute to the model and were not significant
(p>.05). The coefficient (B) revealed that the odds of UTI antibiotic resistance was .000
more likely for those prescribed combined broad- and narrow-spectrum antibiotics. The
Sig. (p>.05, .995) concluded that combined broad- and narrow-spectrum antibiotics
prescribed were not statistically significant, therefore I failed to reject the null hypothesis;
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there was insufficient evidence at the alpha level to reject the claim that combined broadand narrow-spectrum antibiotics prescribed is related to UTI antibiotic resistance. The
odds for those patients who were prescribed combined broad- and narrow-spectrum
antibiotics for symptomatic UTIs were 2.592E+22 (95%CI .000 to .000) more likely to
have UTI antibiotic resistance in an ambulatory care setting when prescribed antibiotics
for a UTI. Since the CI (confidence interval) was 0, the increased odds (2.592E+22) of
UTI antibiotic resistance among nonpregnant females, ages 25-44, and on Medicaid, who
were prescribed combined broad- and narrow-spectrum antibiotics for UTIs at baseline,
were not statistically significant and therefore I failed to reject the null hypothesis.
Predictor characteristics and combined broad- and narrow-spectrum
antibiotics. Predictor characteristics based on descriptive measures of incidence and
prevalence were calculated for combined broad- and narrow-spectrum antibiotics and
UTI antibiotic resistance (see Table 22). The prevalence of UTI antibiotic resistance in
the total number of sample cases with UTI antibiotic resistance (n=45) was 49% when
prescribed combined broad- and narrow-spectrum antibiotics. The incidence rate (new
cases of antibiotic resistant UTIs) for those at risk in 12 months or less was 31%.
Table 22
Predictor Characteristics of Combined Broad- and Narrow-Spectrum Antibiotics
Prescribed
Combined
Broad and NarrowSpectrum
Antibiotics Prescribed

Prevalence

Incidence

49%

31%
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Summary
Three research questions, inclusive of five binary logistic regressions were
conducted with the statistical program, SPSS, to examine possible relationships between
the timing of antibiotic prescribing, either initial antibiotics prescribed within three
months or less, or, antibiotics continued in 12 months or less, and, those classes of
antibiotics prescribed for UTIs (broad-spectrum, narrow-spectrum, and combined broad
& narrow-spectrum), and antibiotic resistance in urinary tract infections in nonpregnant
females, ages 25-44, on Medicaid who sought care in an ambulatory setting. The first
research question explored whether antibiotics prescribed at the onset of a UTI was
associated with antibiotic resistance. The results of the first binary regression indicated
that there was no impact on UTI antibiotics resistance within 3 months or less and initial
antibiotics prescribed. Additionally, there was no impact with initial antibiotics
prescribed and the age of the patient or the region where the visit took place. The second
research question explored whether antibiotics that were continued for recurrent UTIs
that had been initially treated previously in an ambulatory care setting, were associated
with antibiotic resistance. Results of the second binary regression indicated that there was
no impact on UTI antibiotics resistance within 12 months or less and continued
antibiotics prescribed. Additionally, neither age or region was impacted by continued
antibiotic prescribing. The third question explored whether the class of antibiotics
prescribed for UTIs impacted antibiotic resistance. Results of the third binary regression
indicated that there was no impact on UTI antibiotics resistance and broad-spectrum,
narrow-spectrum, or combined broad- and narrow-spectrum antibiotics prescribed.
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Additionally, there was no impact found with the age of the patient, or the region where
the visit took place.
The study findings will be investigated and explained further in Chapter 5.
Chapter 5 will compare the findings with the literature review and background of the
theoretical framework. Chapter 5 will additionally provide recommendations based on
this study’s limitations, as well as examine the potential for social change while
providing recommendations for future antibiotic prescribing practice in health care.
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Chapter 5: Discussion, Conclusions, and Recommendations
The purpose of this quantitative study was to examine nonpregnant U.S. female
patients who were exposed to poverty, as evidenced by Medicaid, the reported payment
type, and, at risk for antibiotic resistance when seeking care for UTIs in ambulatory care
settings. The exploration of those relationship potentials with UTI antibiotic resistance
and prescription timing laid the groundwork for larger cause-effect studies that should be
conducted in the future. This study’s sample was small; however, findings indicate that
the broad-spectrum class of antibiotics continue to be overutilized. Additionally, the
prescribing of combined classes of antibiotics, broad- and narrow-spectrum, may be an
increasing concern to consider and not simply an artifact results related to a small study.
The significance of this research study is to distribute education associated with
negative outcomes related to the inappropriate prescribing and utilization of antibiotics in
the treatment of UTIs in an ambulatory clinic setting. Specific classes of antibiotics were
selected to find out if these had an impact on UTI antibiotic resistance. Relationships that
may occur between the timing of when antibiotics are prescribed and UTI antibiotic
resistance were also examined. To my knowledge, this is the first study of its kind to
utilize the NAMCS data to examine the relationships among antibiotic prescribing and
UTI antibiotic resistance in low-income women in an ambulatory clinic setting.
Five binary logistic regressions were executed with the three research questions
posed utilizing a statistical program, SPSS 23. Binary logistic regression analyzed
relationships between the timing of antibiotic prescribing and UTI antibiotic resistance.
Before regression was carried out, descriptive statistics were executed; frequencies, cross
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tabs, and prevalence were calculated and reviewed. I found that 91% of nonpregnant
women between the ages of 25-44 and on Medicaid and who followed up at an
ambulatory care clinic were more likely to be prescribed broad-spectrum antibiotics
initially and, also, when continued on antibiotics for a UTI. Women who required followup for recurrent UTIs were continued on antibiotics 85% of the time; of those, 73% were
antibiotic resistant to broad-spectrum antibiotics.
Interpretation of the Findings
The diagnosis and treatment of UTIs and their association with antibiotic
resistance have significant implications for patient health and costs associated with health
care (Magliano et al., 2012). According to Langdon, Crook, and Dantas (2016), researchbased studies in the United Sates are valuable for the identification of factors that may
negatively alter resistance rates in underserved populations, such as nonpregnant women
on Medicaid. However, pregnant female Medicaid populations have been the focus of
UTI antibiotic research because of potential teratogenic effects on the fetus (Minardi et
al., 2011). Efforts should be made to increase the prediction of antibiotic-related UTIs for
the women on Medicaid and supported by financial, pharmaceutical, demographic data.
Efforts should also be made to increase the research grants issued in this area.
In the United States, the rate of UTIs are greater than 13,000 per 100,000 adult
women per year (Kattan & Gordon, 2013). UTI prevalence studies appear to evidence
wide fluctuations in reporting depending on the population being studied. Both pregnant
and nonpregnant females have been reported to have the same prevalence rates with
community-acquired UTIs, however, pregnant females have been the focus research
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studies in the United States (Salem & El-Azab, 2011; Anozie, Lawani, Esike, Mamah, &
Ajah, 2016).
Literature reviewed for this study combined the most current study outcomes and
research history related to community-acquired UTIs nonpregnant women in low-income
populations in the United States. Females between the ages of 25-44 were found to be the
most likely group to become resistant to antibiotics according to one of the earliest
studies on UTIs and antibiotic resistance in an ambulatory setting (Butler, Hillier,
Roberts, & Dunstan, 2006). In one large multi-year study between 2002-2008, over 35%
of female patients on both Medicare and Medicaid were found to have uncomplicated
UTIs, however, all study participants were over the age of 18, therefore age as a
confounder was not controlled for and antibiotic utilization and resistance were not
discussed.
The mean age for nonpregnant women in my study population who developed
antibiotic resistance in uncomplicated UTIs was 33 years of age (age range 25-44). This
was consistent with the uncomplicated study element and findings by Kobayashi et al
(2016) indicating that women in the age range of 30-49 had a higher percentage of
uncomplicated UTI occurrences in ambulatory care settings (35%). Kobayashi et al,
however, did not incorporate antibiotic utilization and resistance factors into their study.
Geographically, my study evidenced a higher occurrence with uncomplicated UTIs in
low-income women in the Southern region of the United States than other states. The
Southern U.S. regional data reported by Kobayashi et al. was consistent with my study
finding that the Southern United States had the highest rates of occurrence (27%) in
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uncomplicated UTIs. My study however, produced a small reduction in occurrence
outcomes with uncomplicated UTIs in low income females from the South (44%)
compared to the Western United States (24%). However, both the South and the Western
regions of the United States had a higher percentage of UTI occurrences than the
Northeastern (22%) or Midwestern (16%) United States. As I could not find similar
studies conducted to date in the Unites States related to uncomplicated UTIs in lowincome female populations, I used references of results identified in global studies.
Broad-spectrum antibiotics are the most appropriate class of antibiotics in the
empiric treatment of UTIs (Merli et al., 2016). They are normally prescribed for just a
few days of treatment after the initial diagnosis, however it is becoming more common to
find UTIs that need prolonged treatment (Mazzulli, 2012; Lamb, 2016). Antibiotic
resistance may occur when a provider fails to order a timely urine culture, or, the
laboratory does not reflex a urine test when the urinalysis meets a specific threshold
(Eliopoulis, Cosgrove, & Carmeli, 2003; Wolf, 2016); as a result, inappropriate
antibiotics are prescribed (Humphries & Dien Bard, 2016). This type of care can increase
resistance patterns either already present, or provides an environment for resistance to
occur (Lee, Cho, Jeong, & Lee, 2013).
This study indicated that 91% of nonpregnant females on Medicaid were
prescribed antibiotics initially for symptomatic UTIs. Of these patients, 84% were
continued on antibiotics in 12 months or less. This means that only 7.2% of the Medicaid
nonpregnant female population who were initially prescribed antibiotics may not have
been treated adequately or appropriately and had to return for further UTI antibiotic
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treatment. Of those patients (initial and continued combined) who were prescribed
antibiotics and became resistant, 79% were prescribed broad-spectrum antibiotics, 31%
were prescribed narrow-spectrum antibiotics, and 57% were prescribed a combination of
broad- and narrow-spectrum antibiotics. This study’s sample outcomes appeared to be
consistent with current treatment guidelines indicating that the administration of broadspectrum antibiotics should be reduced for suspected UTIs (Goodman et al, 2016);
providers appear to be overprescribing broad-spectrum antibiotics. Although not included
in the analysis, this study’s initial case review anecdotally noted that fluoroquinolones
were the primary broad-spectrum category of antibiotics prescribed initially for UTIs.
Most of the nonpregnant female Medicaid cases in the sample population (n=45)
had evidence of UTI signs and symptoms per the NAMCS codebook; 89% of the sample
was recorded as having a UTI signs and symptom. Those patient cases that did not have
signs and symptoms evident, had a UTI diagnosis code present per ICD-9 coding (5990).
Access to a complete medical chart was not available to review the rationale for those
sample cases that did not meet UTI signs and symptoms study criteria (11%, or, 5 cases)
but were coded as a UTI (5990). Several cases in the sample additionally did not meet for
UTI resistance criteria, but were noted to have been prescribed initial or continued
antibiotics. The initial or continued antibiotics coded in relation to UTI resistance was
documented with an ICD-9 diagnosis code for a medical condition other than UTI, even
in the presence of an ICD-9-documented UTI code, therefore these cases did not meet
criteria for UTI antibiotic resistance. Since each of the patients in the sample had
laboratory evidence of a urinalysis and had an ICD-9 code of “5990” documented, initial
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or continued antibiotics should have been prescribed according to practice
recommendations (IDSA, 2011).
Ecosocial Theory and Interpretation of Findings
In Chapter 2, I described an ecosocial interactive method of analysis framework
for disease inequalities, distribution, and a population’s health (Krieger, 2008). As a
result, the study increased the understanding for one social determinant, poverty, as
evidenced by Medicaid, and the roles/influential characteristics that prescribing any class
of antibiotic at any stage of a UTI, has on the nonpregnant female population. Population
health distribution (health outcomes) includes antibiotic susceptibility (Penders,
Stobberingh, Savelkoul, & Wolffs, 2013) as well as other tangible and psychological care
for a UTI, all of which are at the heart of population distribution. Pathways from health
distribution leads to the process of UTI treatment. Inequalities of class, race, ethnicity,
and gender surround population health distribution as these pathways are traveled.
Healthcare-provider competency weighs heavily on antibiotic exposure outcomes, and
these prescribing decisions are often not based on hard evidence (lab test results, for
example), but based on the interactions between the patient and provider (Meropol,
Mercalio, & Metlay, 2013).
Studying a social determinant was pertinent in the analysis of poverty and
antibiotic resistance. The ecosocial theory approach anticipates large and small scalelevel effects on a social determinant such as poverty and health outcomes (Krieger,
2005). Additionally, individual beliefs are determinants on a patient’s health outcome
which can affect every aspect of a patient visit (Krieger, 1994; Krieger, 2001; Krieger,

112
2008). Every woman that experiences poverty in this study must be able to reference how
their care should be when they go to an ambulatory care setting with symptoms of a UTI.
They should be able to intrinsically evaluate how decisions for their care are made so that
they can deter future risks of occurrence or recurrence. Group-level knowledge is also
important, especially today with social media (Krieger, 2008; Krieger, 2012). An
individual can connect with others on the internet and find out about experiences, or,
access how providers are “graded” (Woods et al., 2013). Each patient, no matter what
language they speak or what social class they are from should be able to understand what
constitutes treatment with dignity by the provider and other health care staff (Dickert &
Kass, 2009); those with disabilities will have to rely on their caregiver for this, which
may or may not be a bias (Seibert, Stridh-Igo, & Zimmerman, 2002) on the pathway to
care.
Disadvantaged groups have been known to have barriers with access to care, and,
those processes that affect appropriate management (Artiga, 2016). A Harvard staff
writer stated, “You don’t have to travel all the way to Malawi, you can go to any rural
house in America” (Powell, 2016, p.1) (regarding where to find overlooked health
inequalities). Inequalities are representative of the structural inequalities found in society
that include economic, political, and social (Krieger, 2012). Determinants can influence
UTI antibiotic management and access to the right provider, laboratory, diagnostic, or
pharmacy services. The distribution of nonpregnant females on Medicaid that encounter
symptoms of a UTI may will go one of two ways: the UTI goes away after initial
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antibiotics are prescribed, or, the UTI is recurrent and antibiotics must be continued.
Either way the Medicaid patient must be treated the same as any other patient.
The complexity with both initial antibiotic prescribing and continued antibiotic
prescribing for UTIs can further influence the ecosocial diagram. These aspects of care
by medical providers will significantly impact a patient’s health outcome and future
outcomes. Unfortunately, when a symptomatic patient presented for care in my study,
due to not having access to a complete medical chart that could have documented other
signs and symptoms of UTI, the review of the provider’s choice of antibiotics, and
objective, and subjective content, could not be ascertained. Several cases clearly did not
have antibiotics issued, although they had positive signs and symptoms of a UTI and had
a urinalysis performed. Many Medicaid patients who were prescribed antibiotics at their
initial appointment also came back to be re-treated for their UTIs. There was additionally
evidence of no treatment, yet Medicaid patients returned to their provider for treatment,
therefore, treatment occurred after the initial appointment somewhere. It is unknown
without a complete medical record, whether there was a reason noted by the provider
about why antibiotics were not prescribed for a positive urinalysis and signs and
symptoms of UTI criteria were met and if the patient was referred to an ED for treatment.
My study supported findings that a urinalysis should be conducted and antibiotics
prescribed for complaints if UTI symptoms were also present (Bates, 2013). A urinalysis
is not recommended for asymptomatic bacteriuria (Abbo & Hooton, 2014). There were
no patients in my study with asymptomatic bacteriuria who underwent a urinalysis, and
coded with a UTI. Studies in the literature have concluded that in the presence of positive
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nitrites and leukocytes found on a urinalysis (Simon, 2012), however, a UTI should
always be included in the differential as it is usually indicative of a bacterial UTI; a
bacterial UTI in the presence of positive symptoms and patient history should always be
treated with an appropriate antibiotic (Mody & Juthani-Mehta, 2014).
An initial review of the data collected for my study before analysis was conducted
indicated that 3 out of 45 (7%) patients returned to their primary care provider for a
recurrent UTI and was prescribed initial antibiotics elsewhere. Therefore, these Medicaid
patients saw their provider, were not treated, went elsewhere for care for their UTIs, were
prescribed antibiotics, then returned to the original healthcare-provider that they saw
initially because they were still having UTI symptoms. A diagnosis code was created to
represent a UTI when the Medicaid patients were initially seen, however, they were not
prescribed initial antibiotics. This information is consistent with one study that reported
that after an initial diagnosis in primary care was made, an emergency department (ED)
visit will occur 68% of the time, or, 180 days from the original diagnosed medical
condition (Lash et al., 2017). Without the full medical chart, I was unable to deduce
where the initial antibiotics prescribed had come from. It was already known that their
primary providers that they saw initially when their UTI symptoms first occurred, were
present, as indicated by the data, however they were not prescribed initial antibiotics. I
could have hypothesized that these patients consulted with an ED after they did not
receive initial UTI treatment from a primary provider. However, again, without the full
medical chart, I was unable to confirm this for this study.
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Evidence that patients on Medicaid are seeking care for simple medical problems
in an ED or urgent care clinic is much costlier for treatment than by a primary provider
and not appropriate (Kellermann & Weinick, 2012). Patients on Medicaid should not
have to resort to an ED or urgent care clinic for the care of an acute, uncomplicated UTI.
According to Kellermann & Weinick (2012), in a study that spanned two decades,
involved anonymous callers who phoned primary care clinics posing as Medicaid patients
and asked if they accepted Medicaid for minor treatment. When the answer was “no”
they did not accept Medicaid, there was a 26% response-rate of being referred to an “ED”
for treatment. My study supported findings by Kobayashi et al that initial treatment with
antibiotics by a primary care provider for UTIs (2016) should be recommended for those
patients on Medicaid and not an ED (2012; Trinh & Klinker, 2015). This was evidenced
in my study with 26 out of 45 Medicaid patients (58%) that had to undergo continued
treatment (recurrence) of the initial UTI; Medicaid patients should be afforded the same
continuity of care as anyone else. Therefore, were those 3 patients possibly told upon
discharge from their own primary care provider to follow up at an ED if they had any
further problems versus coming back for care again? Siek, Hefner, Wexler, Taylor, &
McAlearney (2016) found that cultural and other educational issues may be a barrier to a
patient’s perception of their need for an emergency department.
Patient’s truly may not understand why they would be referred for further
problems to an ED, if it also was not explained that care for the same problem, that was
not an emergency, should bring them back to their primary care provider. Education with
the medical staff about how to communicate with patients should always be reviewed by
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another competent medical staff supervisor (Gesme, Towel, & Wiseman, 2017). A
Medicaid patient who is seen in an ED for an uncomplicated UTI after being diagnosed
in a clinic, then re-treated in the ED, is disadvantaged because the provider that they
return to after an ED appointment, may not have laboratory results or other diagnostic
information to enable them to continue these patients on antibiotics appropriately,
whereby, creating an environment for UTI antibiotic resistance.
Interpretation of Statistical Findings
The sample of 45 nonpregnant female patients, ages 25-44, and on Medicaid were
all positive for UTI diagnosis, yet 41 (91%) of these patients received initial antibiotics in
3 months or less. Of the 41 patients who were prescribed antibiotics in 3 months or less,
21 (51%) became UTI antibiotic resistant. Of the 41 patients who received initial
antibiotics and became UTI antibiotic resistant, 11 (27%) received a broad-spectrum
antibiotic, 4 (10%) received a narrow-spectrum antibiotic, and 4 (10%) received a
combined broad- and narrow-spectrum antibiotic. Of the sample (n=45), 26 patients
(58%) were continued on antibiotics within 12 months or less from their initial UTI
diagnosis. Of the 26 patients who were continued on antibiotics, 22 (85%) became UTI
antibiotic resistant. Of the 22 patients who received continued antibiotics in 12 months or
less and became UTI antibiotic resistant, 16 (73%) were prescribed broad-spectrum
antibiotics, no patients were prescribed narrow-spectrum antibiotics, and 3 (14%) were
prescribed combined broad- and narrow-spectrum antibiotics. Of the sample (n=45) who
became UTI antibiotic resistant, 3 (7%) were prescribed both broad-spectrum and a
combined broad- and narrow-spectrum antibiotic on the initial appointment; patients were
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never prescribed combinations of narrow-spectrum or combined broad- and narrowspectrum at their initial appointment. Therefore, my study findings indicated that over
half (51%) of those non-pregnant females, ages 25-44 and on Medicaid, who were
prescribed antibiotics during their initial appointment in ambulatory care for UTI
symptoms, became UTI antibiotic resistant. The predominant antibiotic prescribed that
was associated with UTI antibiotic resistance was broad-spectrum antibiotics.
Additionally, this study indicated that 84% of those nonpregnant females between 25-44
years of age and on Medicaid who followed-up with recurrent UTI symptoms, and were
prescribed antibiotics, and had a positive outcome of UTI antibiotic resistance, were
predominantly prescribed broad-spectrum antibiotics. These findings concur with Shapiro
et al (2013) who conducted the only adult study published in the United States at th333is
time on antibiotic utilization in an ambulatory care setting, that concluded that broadspectrum antibiotics were prescribed more than any other antibiotic.
Limitations of the Study
There are multiple study limitations that need to be acknowledged. First, this
study was limited using secondary data; I neither directed nor supervised the collection of
the survey data. The second limitation was the relatively small sample size. Data was
assumed to be accurately collected, however, prior to the year 2012 the category code
describing gestational status identified as “Pregnant” (NAMCS, 2012) was not available
as a variable for analysis. To compensate for the absence of an all-inclusive variable and
ensure internal validity of this status prior to 2012, NAMCS code books were used to
identify codes related to pregnancy. Possible underreporting of UTI
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diagnoses may have been related to erroneous sampling and coding errors in the sample
frame as evidenced by the limited number of UTI cases identified for this study. Other
research studies that have utilized NAMCS data have also expressed the possibility with
potential coding issues (May, Mullins, & Pines, 2014). During data validation of the
secondary data source codes for my study, NAMCS secondary codebook codes were
substituted for ICD-9 codes at times resulting in errors in the interpretation of a
diagnosis, therefore those cases were not included. All codes were reviewed for accuracy
during my study’s internal validation process.
The final case count after all related codes were abstracted indicating that only 51
cases of UTIs were recorded. I questioned this and made an inquiry to NAMCS. NAMCS
responded with a concurrence to my findings, except that they found even less than I had
because they did not include both upper and lower UTI codes, only those that were coded
specifically as “UTI” (ICD-9 code 5990). A closer review may indicate that there is
substantial underreporting with UTIs, or, coding errors are an issue in ambulatory care
settings. Global research studies provide data that strongly support the notion that lowincome nonpregnant women between the ages of 25-44 who have been treated in
ambulatory care clinics for uncomplicated UTIs are a high-risk population that deserves
to be further studied.
The sample frame represented all 4 census regions of the United States. Each
population variable (nonpregnant, female, and Medicaid) was represented in this national
survey. My choice of conducting a retrospective cohort study narrowed the availability of
potential confounding factors resulting in selection bias (Euser, Zoccali, Jager, & Dekker,
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2009; LaMorte, 2016) however, a prospective study would have been hindered by time
and expense (Song & Chung, 2010). Song and Chung (2010) stated that a retrospective
study is a refined and efficient way to conduct research studies because of the ability to
use historical data. Fisher’s exact test was the obvious choice for analysis due to the small
number of cases. The smaller sample produced an overestimation in the odds ratios which
was due to the use of logistic regression (Nemes, Jonasson, Genell, Steineck, 2009). A
larger study sample may have produced more robust results by providing an adjustment
with additional confounders, and decreased the potential for a biased odds ratio that may
have led to an overestimation of the effect measure.
At this time, there is no gold standard available to measure how to prevent
uncomplicated UTI antibiotic resistance in nonpregnant women. There is no way to know
the sensitivity and specificity of implied analysis. Confounders such as geographical
regions were used because according to the literature search antibiotic susceptibility,
because of inappropriate utilization patterns, regional politics, or regional patient
behaviors and access to care, are related to antibiotic resistance. A larger study to assess
the causal effects of geographical region on antibiotic resistance would be recommended
and this study was limited by the choice of study design.
Generalizability was lacking in my study due to the unexpected small sample size.
A more detailed sample frame of data related to regions, age ranges, and specific
antibiotics that were prescribed for uncomplicated UTI cases could have been used to
substantiate generalizability. Random sampling was conducted because it is not rational
to study an entire population (Kukull & Ganguli, 2012), however this did not improve
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external validation. Kukull & Ganguli (2012) posit that when a study is comprised of
clinic visits, it is less important to focus on generalizability and more important to capture
the accuracy in diagnostics. The authors explain that any study’s results that are clinicbased can become negatively skewed if the disease in question is not identified properly,
and, any misclassification of disease (those that are positively versus negatively
diagnosed) may diminish and misconstrue results of a study (Kukull & Ganguli, 2012).
Internal validation for my study clearly confirms that the disease was classified properly.
The extent to which my study results could be generalized may be a consequence in
choice of confounders controlled for. This study explored age and region as confounders
because of the associations with antibiotic resistance exposures already documented in
UTIs. This introduction was used to attract other researchers and motivate towards the
engagement of future research in this area.
The third limitation was that this study did not allow inference for causes and
effects, therefore data associations were limited. Underlying medical conditions and
detailed antibiotic dosing that could have been associated with UTI symptom
management and antibiotic resistance were found to be unreliable for analysis. For
example, indicators often used to “define daily dose (DDD)” (p. 5) according to
Schechner, Temkin, Harbarth, Carmeli, & Schwaber (2013) in cohort studies were not
available. DDD may over-, or, under- generalize results (Schechner et al., 2013). Further
analysis of appropriate variables that are time-dependent may be one key to inappropriate
antibiotic prescribing for UTIs. This may be accomplished by the interpretations of the
relationships between the initial provider appointment activities and future appointments
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linking the same patient with continued UTI symptoms. The final limitation was
evidenced by the analysis outcomes for initial and continued prescribing of antibiotics
and antibiotic resistance. Initial and continued prescribing of antibiotics hypothesized as
factors contributing to antibiotic resistance was not found to be statistically significant.
The allocation and timing of antibiotics once a patient was discharged could not be
determined.
Recommendations
Future research to overcome the limitations found in this study is crucial. Data
must be thoughtfully collected and interpreted so that the results can be applied to actual
ambulatory care settings. Although the sample size was small and generalizability was
difficult to produce, the obvious overutilization of the broad-spectrum class of antibiotics
evidenced by this study’s outcomes substantiates the notion that these antibiotics are the
main cause for antibiotic resistance (CDC, 2013). It is recommended that subsequent
studies should attempt to include medical record details from a broad, general,
nonpregnant female Medicaid ambulatory care population, between the ages of 25-44,
that is a nationally representative sample, and anticipate if antibiotics are clinically
indicated for UTIs. This information should be utilized for a cause and effects study that
can interpret those barriers with antibiotic prescribing and resistance in this population.
This data may then potentially be utilized by a team of companies, private and public,
such as pharmacies, laboratories, emergency departments, and ambulatory health clinics,
to put their resources together and propose a plan for antibiotic prescribing. Conditions
that lead to hospitalizations, known as ambulatory care-sensitive conditions (ACSC)
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appear to also be prevalent (Mkanta, Chumbler, Yang, Saigal, & Abdollahi, 2016) with
UTIs. Many studies have already shown that there are multiple disconnects and barriers
to appropriate prescribing that are dependent on the many levels related to type of care
that a patient must receive once they are symptomatic with a UTI (Hossain & Laditka,
2009; Kellermann & Weinick, 2012).
The need to include a larger sample is highly recommended due to the altered
relationships that were seen with the distribution and odds ratios with binary logistic
regression; the power needs to be increased. Variables that are more robust would serve
this study well. The variables of age and region in this study, although categorized
appropriately, did not provide enough of a relationship and the outcome was a poor
model fit. Statistical significance may have improved, however, possibly age and region
may have seen a more generous relationship had the sample size been larger.
Antibiotic class-induced antibiotic resistance has been well documented (Harbarth
et al., 2015; Ventola, 2015) while the discrete prescribing of nonpregnant Medicaid
females in the development of UTI antibiotic resistance has not (Minardi et al., 2011;
Eells, Bharadwa, McKinnell, & Miller, 2014). Studies that could utilize U.S. licensed
antibiotic agents of all classes to treat UTIs with nonpregnant female Medicaid
populations would augment the knowledge currently published and identified by this
literature gap.
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Implications
This study’s’ conclusions afforded an improved understanding of UTI antibiotic
resistance epidemiology in this distinct, and impoverished UTI-positive population. This
study additionally provided significant implications for social change. An improved
understanding can be groundbreaking for new areas of inquiry, and lead to necessary
future studies. The main goal of antibiotic stewardship in the United States and globally,
is to minimize potential harm that may come to patient’s due to the inappropriate
treatment of antibiotics. UTI incidence of antibiotic resistance before and after
implementing antibiotic stewardship programs has been described across the United
States, however, this has only been studied in hospitalized patients, pregnant women, or
long-term care patients with urinary catheters (May, Mullins, & Pines, 2014; Shapiro et
al., 2013; Mkanta et al., 2016).
Antibiotic stewardship is new to ambulatory care clinics; infection control
surveillance, other than outpatient surgery, and more recently, outpatient dialysis (CDC,
2011c, p. 1), currently does not have a way to appropriately collect denominator data.
Recent government attention though has created grants and other opportunities for study
in order to create appropriate surveillance programs for ambulatory care (Magill,
Dumyati, Ray, & Fridkin, 2015). This research study revealed that there continues to be
inappropriate prescribing with broad-spectrum antibiotics in particular, but additionally,
narrow-spectrum and combined broad- and narrow-spectrum. Additionally, follow-up
visit communication after the initial antibiotic have been prescribed to nonpregnant
females on Medicaid appears to be an issue. Therefore, the need to further study
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communication activities upon discharge in outpatient settings with nonpregnant
Medicaid when they are prescribed antibiotics could be a crucial step in antibiotic
stewardship endeavors. Organizational and local levels in outpatient medicine could be
influenced from epidemiology studies produced about nonpregnant female Medicaid
patients’ timing of antibiotics and discharge communication.
The relationship between antibiotic delivery in ambulatory care settings and the
epidemic crisis of antibiotic resistance may benefit health-care providers. This may be
related to communication education that has been in the spotlight for informing
prescribing decisions that they will have to make. To implement comprehensive
evidence-based measures with communication education for health-care providers about
impoverished nonpregnant women and UTI antibiotic stewardship, more research studies
are greatly needed, however individual state legislation and Medicaid also should be a
priority for legislation. Antibiotic stewardship that leads to resistance with UTIs in the
population are current health care issues affecting ambulatory care settings where
Medicaid patients are often seen for care. Disparities in health care and poverty have
been persistent and long-standing because Medicaid has not been expanded in 19 states in
the United States; as of 2017, the coverage gap under the Affordable Care Act (ACA)
remains uncertain because of the ability for states to opt out (CNBC, 2016; KFF, 2016;
Johnson, 2016; Advisory Board, 2017).
Ambulatory care patients on Medicaid need to increase their understanding of
how UTIs are contracted to prevent or decrease antibiotic resistance and further
complications that could result because of inappropriate treatment that includes antibiotic
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prescribing. The key to prevention is active participation regardless of social economic
status (Vahadat, Hamzehgardeshi, Hessam, & Hamzehgardeshi, 2014). The internet is
free and available to anyone, in locations such as the library, schools, or even public
health clinics. Also, in today’s modern world, even those on Medicaid may be eligible to
have a free cellular telephone, which may come with internet access (Federal
Communications Commission, 2017). Individuals who arm themselves with antibiotic
knowledge are be more likely to take their medications as prescribed, or, discuss the
rationale for an antibiotic prescribed before even taking it (Awad & Aboud, 2015).
These proactive interventions are likely to reduce health care visits to ambulatory
settings as well as hospitalizations for complications of UTIs. This would unfortunately
need to be under tight surveillance; a resource not a priority in the ambulatory care
setting. The person(s) providing the surveillance would need to be able to promptly report
data to the providers onsite as well as educate them in the moment. Awareness at the time
that a decision is made that could have a negative impact (active surveillance required),
rather than passive, or, retrospective surveillance, and, education that may be lost to
meaning as time moves beyond the problem, is needed. Real-time data that shows a
healthcare-provider what their decisions are doing, will impact the patients’ future care.
Health-care providers usually want to do what is right for any patient. There are
providers, however, who have practiced medicine a certain way for such a long time, and
may severely resist change, no matter how much data they are shown. These providers
may also be reluctant to engage in any educational confrontations and may take offense
to someone proposing to do this, even to help them and improve their patients’ care
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outcomes (Sillito, 2016). Although for our canine brethren, an old dog may learn slower,
but they will be able to learn a new trick (Coren, 2016), this does not decrease the
necessity for provider responsiveness to antibiotic resistance education. Cross-cultural
education may be stated as a “soft science” (Kripalani, Bussey-Jones, Katz, & Genao,
2006, p. 1118), however, a reduction in morbidity and mortality that can be clearly
viewed, may be the positive after-effect when communication education is provided to
those that prescribe to the underserved population.
Conclusions
The purpose of this retrospective observational cohort study was to investigate
nonpregnant American female patients on Medicaid who were at risk for UTI antibiotic
resistance. The aim of this study was to understand the relationships between prescription
timing and classes of antibiotics that were prescribed for uncomplicated UTIs treated in
an ambulatory care setting. The regression analysis for the three research questions did
not prove to be significant. However, this small study pointed at the same indications
about antibiotic resistance that is currently found in the literature; broad-spectrum
antibiotics are overutilized no matter when they are prescribed and are likely the
offenders of antibiotic resistance in UTIs.
The descriptive statistics results, proved to be worthy of analysis. This activity
provided evidence in support of continued antibiotic research. Rearranging the class of
antibiotic accordingly may decrease the number of those returning with recurrent UTIs.
Specific antibiotics within the classes was not analyzed in this study. Furthermore, this
study had indicated that there was a minuscule trend that may be indicative of poor
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discharge communication. This was evidenced by a lack of antibiotic prescribed at the
initial appointment, however, the recurrence of UTI symptoms and a return appointment
indicated that antibiotics were continued. This was worrisome for both the patient and the
provider. The patient, without clear discharge instructions may have misinterpreted being
told to go to an emergency room if the problem continued. This could have been
remedied by simply saying to return to the provider office if the problem continued, or,
state that only in the case of an emergency (and provide parameters that the patient can
understand, such as a fever of 104 or greater) they may need to go to an emergency room
for care. Consistent messaging is an important piece of a patient care visit no matter what
type of patient the care is for, or where they decide to go for care. It is important to
remember that the patient has choices and will go where they feel comfortable and cared
for.
Future research with antibiotic stewardship should target UTI antibiotic resistance
reduction endeavors to decrease UTI resistance frequency by addressing inappropriate
prescribing and utilization in the nonpregnant female Medicaid population. This study
portrayed the need to focus future research on appropriate antibiotic prescribing and
make it a primary goal to include disparate populations, such as those on Medicaid. The
ultimate focus, however, should be on decreasing unintentional negative outcomes of
antibiotic prescribing practices.
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